<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Med Sci (Basel)</journal-id><journal-id journal-id-type="publisher-id">medsci</journal-id><journal-title-group><journal-title>Medical Sciences</journal-title></journal-title-group><issn pub-type="epub">2076-3271</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407542</article-id><article-id pub-id-type="pmc">PMC12101198</article-id>
<article-id pub-id-type="doi">10.3390/medsci13020047</article-id><article-id pub-id-type="publisher-id">medsci-13-00047</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hunt</surname><given-names>Sunny</given-names></name><xref rid="af1-medsci-13-00047" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Thyagarajan</surname><given-names>Anita</given-names></name><xref rid="af2-medsci-13-00047" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3857-9073</contrib-id><name><surname>Sahu</surname><given-names>Ravi P.</given-names></name><xref rid="af2-medsci-13-00047" ref-type="aff">2</xref><xref rid="c1-medsci-13-00047" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Torres</surname><given-names>Antoni</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-medsci-13-00047"><label>1</label>Department of Chemistry and Biochemistry, Oberlin College, 173 W Lorain St, Oberlin, OH 44074, USA; <email>shunt1@oberlin.edu</email></aff><aff id="af2-medsci-13-00047"><label>2</label>Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Dayton, OH 45435, USA; <email>anita.thyagarajan@wright.edu</email></aff><author-notes><corresp id="c1-medsci-13-00047"><label>*</label>Correspondence: <email>ravi.sahu@wright.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>47</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>09</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Cancer is the second leading cause of mortality worldwide. Despite the available treatment options, a majority of cancer patients develop drug resistance, indicating the need for alternative approaches. Repurposed drugs, such as antiglycolytic and anti-microbial agents, have gained substantial attention as potential alternative strategies against different disease pathophysiologies, including lung cancer. To that end, multiple studies have suggested that the antiglycolytic dichloroacetate (DCA) and the antibiotic salinomycin (SAL) possess promising anticarcinogenic activity, attributed to their abilities to target the key metabolic enzymes, ion transport, and oncogenic signaling pathways involved in regulating cancer cell behavior, including cell survival and proliferation. We used the following searches and selection criteria. (1) Biosis and PubMed were used with the search terms dichloroacetate; salinomycin; dichloroacetate as an anticancer agent; salinomycin as an anticancer agent; dichloroacetate side effects; salinomycin side effects; salinomycin combination therapy; dichloroacetate combination therapy; and dichloroacetate or salinomycin in combination with other agents, including chemotherapy and tyrosine kinase inhibitors. (2) The exclusion criteria included not being related to the mechanisms of DCA and SAL or not focusing on their anticancer properties. (3) All the literature was sourced from peer-reviewed journals within a timeframe of 1989 to 2024. Importantly, experimental studies have demonstrated that both DCA and SAL exert promising anticarcinogenic properties, as well as having synergistic effects in combination with other therapeutic agents, against multiple cancer models. The goal of this review is to highlight the mechanistic workings and efficacy of DCA and SAL as monotherapies, and their combination with other therapeutic agents in various cancer models, with a major emphasis on non-small-cell lung cancer (NSCLC) treatment.</p></abstract><kwd-group><kwd>non-small-cell lung cancer</kwd><kwd>drug repurposing</kwd><kwd>dichloroacetate</kwd><kwd>salinomycin</kwd><kwd>chemotherapy</kwd></kwd-group><funding-group><award-group><funding-source>NIEHS R21</funding-source><award-id>ES033806</award-id></award-group><funding-statement>The financial support from the NIEHS R21 Grant ES033806 (to R.P.S.) is greatly appreciated.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-medsci-13-00047"><title>1. Introduction</title><p>Globally, the incidence of many common cancers is increasing, which has contributed to cancer becoming the second leading cause of mortality in the United States and worldwide [<xref rid="B1-medsci-13-00047" ref-type="bibr">1</xref>]. The common hallmarks of cancer include deregulated cellular metabolism, sustained cell proliferation, and the development of drug resistance [<xref rid="B2-medsci-13-00047" ref-type="bibr">2</xref>]. Among the various cancer types, lung cancer is the leading cause of cancer-related deaths and the most frequently diagnosed malignant tumor in males and females [<xref rid="B3-medsci-13-00047" ref-type="bibr">3</xref>]. This review highlights the mechanistic workings and efficacy of the antiglycolytic dichloroacetate and the antibiotic salinomycin as monotherapies, and their combination with other therapeutic agents in various cancer models, with a major emphasis on lung cancer, particularly non-small-cell lung cancer (NSCLC) treatment.</p><p>The widespread proliferation of lung cancer can best be attributed to various social factors, such as air pollution and the addictive properties of nicotine-containing inhalants [<xref rid="B3-medsci-13-00047" ref-type="bibr">3</xref>,<xref rid="B4-medsci-13-00047" ref-type="bibr">4</xref>,<xref rid="B5-medsci-13-00047" ref-type="bibr">5</xref>]. However, while these factors offer explanations for the comparatively large proportion of cancer-related deaths (22%), they do not address the high difference in mortality that patients are initially presented with; it is 37% higher among males (37.4 per 100,000 population) than females (27.3 per 100,000) [<xref rid="B6-medsci-13-00047" ref-type="bibr">6</xref>]. To provide answers about these statistics, one must first discuss the multiple lung carcinoma subtypes that patients develop. Non-small-cell lung carcinoma (NSCLC) is the most diagnosed form of lung cancer [<xref rid="B7-medsci-13-00047" ref-type="bibr">7</xref>,<xref rid="B8-medsci-13-00047" ref-type="bibr">8</xref>]. Although it has a 5-year survival rate of 65% in localized stages, it quickly drops to 37% upon metastasis, and down to 9% for advanced forms of the disease [<xref rid="B6-medsci-13-00047" ref-type="bibr">6</xref>,<xref rid="B9-medsci-13-00047" ref-type="bibr">9</xref>]. Small-cell lung carcinoma (SCLC) has a much lower initial 5-year survival rate, starting at 37% and dropping to 3% in advanced metastatic stages. However, a higher proportion of patients are diagnosed with NSCLC, with some figures presenting it as high as 85% of lung malignancy cases [<xref rid="B6-medsci-13-00047" ref-type="bibr">6</xref>]. Despite the seemingly bleak nature of these statistics, most forms of lung cancer, especially those that fall under NSCLC, are still treatable with traditional agents, such as platinum-based chemotherapy, and new approaches, such as immune checkpoint therapy (nivolumab + ipilimumab). However, there continue to be important challenges present in the treatment of NSCLC.</p><p>The common challenges associated with the available therapeutic agents for the treatment of various common cancers, including NSCLC, include drug resistance to molecular-targeted therapies and traditional cytotoxic agents [<xref rid="B10-medsci-13-00047" ref-type="bibr">10</xref>]. For example, elevated levels of the C-Raf proto-oncogene serine/threonine-protein kinase (CRAF) protein can induce resistance to BRAF inhibitors by reducing drug bioavailability. In some patients, BRAF inhibitor resistance can be reversed with MEK inhibitor synergies, but the majority of NSCLC patients will experience disease progression within a year of starting treatment [<xref rid="B10-medsci-13-00047" ref-type="bibr">10</xref>]. Other resistance mechanisms include MET gene amplification [<xref rid="B11-medsci-13-00047" ref-type="bibr">11</xref>]. While customized, targeted treatments in response to NSCLC have clinically proven efficacy, patient outcomes are complicated by tumor heterogeneity that is increased by the onset of metastatic disease [<xref rid="B12-medsci-13-00047" ref-type="bibr">12</xref>]. As a result, oncogenic and acquired resistance continue to create challenges in the treatment of NSCLC.</p><p>Alongside traditional chemotherapy side effects, mutations in oncogenes, such as the epidermal growth factor receptor (EGFR), lead to the activation of tyrosine kinase [<xref rid="B13-medsci-13-00047" ref-type="bibr">13</xref>,<xref rid="B14-medsci-13-00047" ref-type="bibr">14</xref>]. Tyrosine kinases have been shown to catalyze a number of cellular activities, including oncogenic cell proliferation/migration, by contributing to the upregulation of downstream signaling pathways by the phosphorylation of tyrosine residues [<xref rid="B15-medsci-13-00047" ref-type="bibr">15</xref>,<xref rid="B16-medsci-13-00047" ref-type="bibr">16</xref>]. These observations have resulted in the development of tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, and osimertinib, which are frequently part of NSCLC treatment regimens. While targeted molecular therapies, such as TKIs, represent important advancements in cancer pharmaceuticals and are associated with increased survival rates, many patients often develop acquired resistance to these therapies within a year of starting treatment [<xref rid="B17-medsci-13-00047" ref-type="bibr">17</xref>,<xref rid="B18-medsci-13-00047" ref-type="bibr">18</xref>].</p><p>Notably, drug resistance is linked to multiple different mechanisms, one of which is autophagy: the process by which cancer cells remove external molecules from inside their membranes. Epigenetic alteration and tumor heterogeneity are also significant contributors to resistance against targeted therapies, which make NSCLC particularly difficult to treat [<xref rid="B15-medsci-13-00047" ref-type="bibr">15</xref>,<xref rid="B16-medsci-13-00047" ref-type="bibr">16</xref>]. However, resistance mechanisms can be combated by using combination therapies with synergistic cytotoxic effects and repurposing clinically recognized drugs to broaden the amount of usable anticancer medications.</p></sec><sec id="sec2-medsci-13-00047"><title>2. Repurposed Anticancer Agents</title><p>A noticeable proportion of potential anticancer agents have traditionally been used as metabolic regulators, such as metformin and dichloroacetate, both of which target aspects of glycolysis. Their efficacy in pre-clinical studies has been linked to their effect on cancer metabolism (the Warburg effect). The Warburg effect is the phenomenon of cancer cells relying primarily on glycolysis as opposed to oxidative phosphorylation [<xref rid="B19-medsci-13-00047" ref-type="bibr">19</xref>,<xref rid="B20-medsci-13-00047" ref-type="bibr">20</xref>,<xref rid="B21-medsci-13-00047" ref-type="bibr">21</xref>,<xref rid="B22-medsci-13-00047" ref-type="bibr">22</xref>]. Accelerated glycolysis promotes the inhibition of pro-apoptotic factors, such as caspase activity, as well as the increased synthesis of cell DNA and organelles [<xref rid="B19-medsci-13-00047" ref-type="bibr">19</xref>,<xref rid="B23-medsci-13-00047" ref-type="bibr">23</xref>]. Dichloroacetate (DCA), a medication that is primarily used to treat lactic acidosis, has a modulating effect on cancer metabolism. DCA alters the Warburg effect by stimulating pyruvate dehydrogenase (PDH), which causes the inhibition of pyruvate dehydrogenase kinase (PDK). This process causes a switch from glycolysis to oxidative phosphorylation in mitochondria. DCA has been shown to significantly reduce cell migration and proliferation, as well as to promote apoptosis [<xref rid="B24-medsci-13-00047" ref-type="bibr">24</xref>,<xref rid="B25-medsci-13-00047" ref-type="bibr">25</xref>].</p><p>In addition to antimetabolites, among other promising approaches, the ability of antibiotics to target bacteria seems to have overlapping mechanisms with their ability to target cancer stem cells (CSCs). Bactericidal medications function as anticancer drugs by disrupting the mitochondrial processes of CSCs, in the same way they act in prokaryotes [<xref rid="B26-medsci-13-00047" ref-type="bibr">26</xref>]. This aspect is important because cancer tissue, particularly after metastasis, allows antibiotics to mitigate the heterogeneous nature of cancer tissue. CSCs that undergo survival selection are theorized to be, in part, responsible for not only metastasis but also recurrence, compromising further the anticancer treatments that prospective patients may receive. By disrupting the function of CSCs, antibiotics, such as salinomycin (SAL), are potentially able to promote mass-scale apoptosis, and improve survival outcomes by selectively targeting CSCs, which can allow for more aggressive treatment [<xref rid="B27-medsci-13-00047" ref-type="bibr">27</xref>,<xref rid="B28-medsci-13-00047" ref-type="bibr">28</xref>,<xref rid="B29-medsci-13-00047" ref-type="bibr">29</xref>].</p><p>Compared to other novel therapies being developed, such as targeted molecular inhibitors and immunological synergies, studying drugs such as DCA and SAL can reveal how to broaden the scope of potential anticancer agents that can be used. DCA and SAL are both strong examples of why pre-existing pharmaceuticals can be repurposed for anticancer purposes. Metabolic modulators, such as DCA, target cancer metabolism [<xref rid="B24-medsci-13-00047" ref-type="bibr">24</xref>,<xref rid="B25-medsci-13-00047" ref-type="bibr">25</xref>]. They mediate disease progression through mitochondrial stress and often have significant synergistic potential through the same mechanisms. Metabolic modulators tend to be well tolerated and have long histories of chronic clinical use due to the prevalence of disorders, such as diabetes mellitus. SAL is a broad-spectrum anti-microbial that has a powerful targeted apoptotic effect on CSCs [<xref rid="B26-medsci-13-00047" ref-type="bibr">26</xref>]. The effects of SAL indicate the potential efficacy of other commercially available anti-microbials, especially antiparasitic drugs with similar mechanisms. The insights into anticancer mechanisms that therapeutics like DCA and SAL provide will help generate a wider variety of pharmaceuticals that can be used to combat tumor cell proliferation, resistance, metastasis, and recurrence [<xref rid="B24-medsci-13-00047" ref-type="bibr">24</xref>,<xref rid="B25-medsci-13-00047" ref-type="bibr">25</xref>,<xref rid="B26-medsci-13-00047" ref-type="bibr">26</xref>,<xref rid="B27-medsci-13-00047" ref-type="bibr">27</xref>,<xref rid="B28-medsci-13-00047" ref-type="bibr">28</xref>,<xref rid="B29-medsci-13-00047" ref-type="bibr">29</xref>].</p><p>The overall objective of this review is to explore the anticancer properties of DCA and SAL as monotherapies and, when used in combination, as a potential therapeutic option for treating NSCLC. Notably, with its powerful metabolic effect, DCA is a potent synergist that can enhance the selective cytotoxic effects of SAL on CSCs.</p></sec><sec id="sec3-medsci-13-00047"><title>3. Pharmacology of Dichloroacetate</title><p>Dichloroacetate (DCA), or dichloroacetic acid, is a metabolic modulator that is rapidly absorbed into the body by its salt ions and is taken up by cells via the monocarboxylate transport system. To understand the mechanisms of DCA, it is necessary to discuss the pyruvate dehydrogenase complex (PDC), a collection of enzymes found in the mitochondrial matrix. The PDC links cellular glycolysis to the tricarboxylic acid cycle (TCA), as well as to oxidative phosphorylation (OXPHOS). The PDC catalyzes the rate-limiting step in the aerobic oxidation of glucose, pyruvate, alanine, and lactate to Acetyl- CoA, as well as the initiation of OXPHOS. DCA stimulates PDC activation by inhibiting pyruvate dehydrogenase kinases (PDKs). DCA binds to the N-terminal domain of PDK, which prevents it from functioning as a catalyst, reducing the phosphorylation of pyruvate dehydrogenase E1 subunit 1 alpha (PDHE1&#x003b1;), thereby maintaining the PDC in its unphosphorylated form and its role in OXPHOS. As a result, the PDC can continue to aid in the consumption of glucose via OXPHOS [<xref rid="B30-medsci-13-00047" ref-type="bibr">30</xref>,<xref rid="B31-medsci-13-00047" ref-type="bibr">31</xref>,<xref rid="B32-medsci-13-00047" ref-type="bibr">32</xref>].</p><p>DCA was originally investigated as an anti-diabetes drug because of its selective ability to lower blood glucose levels in vivo. PDK is upregulated in diabetes, which oxidizes glucose in the blood and peripheral tissues. However, in non-ketotic type 2 diabetes patients, DCA has also been shown to decrease the amount of lactate and alanine because of its ability to lock the PDC in its unphosphorylated form. The effect of DCA on lactate has long been documented because its most popular clinical application has been in the treatment of lactic acidosis. It is widely considered to be the most effective compound for the reduction in lactate [<xref rid="B32-medsci-13-00047" ref-type="bibr">32</xref>].</p></sec><sec id="sec4-medsci-13-00047"><title>4. DCA as an Anticancer Agent and Its Synergy with Other Therapeutic Agents</title><p>A solid tumor&#x02019;s microenvironment is defined by its disorganized vasculature and prevalent hypoxic zones [<xref rid="B33-medsci-13-00047" ref-type="bibr">33</xref>,<xref rid="B34-medsci-13-00047" ref-type="bibr">34</xref>]. The lack of oxygen induces a metabolic shift to glycolysis, since the mitochondria can no longer rely on oxidative respiration. Hypoxia causes the selective proliferation of cancer cells with high glycolytic metabolisms since they can survive in spaces with limited oxygen. These neoplastic cells then depend on aerobic glycolysis to rapidly proliferate and invade the surrounding tissue. Due to the tumor heterogeneity in many of these cancer cells, glycolysis is transcriptionally upregulated by PDKs, resulting in the suppression of mitochondrial OXPHOS [<xref rid="B35-medsci-13-00047" ref-type="bibr">35</xref>]. Under aerobic glycolysis, there is also an increase in the fermentation of glucose into lactate. Hypoxia-inducible factor 1 alpha (HIF1&#x003b1;) is the gene that encodes PDKs and most all glycolytic processes, inducing other adaptive responses that aid in malignant growth, and has also been shown to interact with oncogene c-Myc to enhance glycolysis [<xref rid="B36-medsci-13-00047" ref-type="bibr">36</xref>,<xref rid="B37-medsci-13-00047" ref-type="bibr">37</xref>]. Its expression is upregulated in cancer due to an accumulation of pyruvate and lactate. DCA has been shown to reduce c-Myc expression by degrading HIF1&#x003b1; through what is suspected to be a post-transcriptional regulation mechanism [<xref rid="B38-medsci-13-00047" ref-type="bibr">38</xref>]. Lactate is involved in tumor survival and proliferation because mono-carboxylic transporter (MTC) proteins shuttle it across the cytoplasm where it is used as a tumor energy source. Lactate drives the process of angiogenesis even under normoxic conditions, and its concentration can be used as a prognostic marker. As discussed previously, DCA redirects mitochondrial metabolism away from glycolysis to OXPHOS by the inhibition of PDKs. The increased stimulation of the PDC catalyzes the rapid oxidation of glucose and lactate, which is associated with the increased expression of HIF1&#x003b1;. DCA increases reactive oxygen species (ROS), which induce downstream changes in mitochondrial function, causing the selective apoptosis of cancer cells. DCA also targets lactate through the same PDK inhibition mechanism [<xref rid="B34-medsci-13-00047" ref-type="bibr">34</xref>,<xref rid="B39-medsci-13-00047" ref-type="bibr">39</xref>,<xref rid="B40-medsci-13-00047" ref-type="bibr">40</xref>,<xref rid="B41-medsci-13-00047" ref-type="bibr">41</xref>,<xref rid="B42-medsci-13-00047" ref-type="bibr">42</xref>,<xref rid="B43-medsci-13-00047" ref-type="bibr">43</xref>].</p><p>The ability of DCA to prevent cancer cell proliferation has been directly observed in A549 and H1299 lung adenocarcinoma cell lines. In a study conducted by Allen and colleagues, it was found that treatment with DCA decreased glucose consumption and lactate production in vitro in a manner that was statistically significant compared to the controls [<xref rid="B42-medsci-13-00047" ref-type="bibr">42</xref>]. DCA was also shown to greatly increase the A549 cell population doubling time. By directing tumor cells to use OXPHOS, DCA inhibits their ability to multiply and therefore proliferate [<xref rid="B42-medsci-13-00047" ref-type="bibr">42</xref>]. While this study did not show that a DCA-induced metabolic shift was able to promote cell apoptosis or necrosis, it enhanced the sensitivity of A549 and H1299 cells to X-ray-induced cell killing. A summary of the in vitro and/or in vivo studies is given in <xref rid="medsci-13-00047-t001" ref-type="table">Table 1</xref>.</p><p>Another anticancer property of DCA is its effect on autophagy, the homeostatic process by which cells degrade organelles and unusable proteins. This process is also a driving factor of acquired chemotherapy resistance [<xref rid="B44-medsci-13-00047" ref-type="bibr">44</xref>,<xref rid="B45-medsci-13-00047" ref-type="bibr">45</xref>]. Autophagy protects cancer cells by encapsulating the anticancer agents within a cell&#x02019;s autophagosomes and degrading them with lysosomal enzymes [<xref rid="B46-medsci-13-00047" ref-type="bibr">46</xref>,<xref rid="B47-medsci-13-00047" ref-type="bibr">47</xref>,<xref rid="B48-medsci-13-00047" ref-type="bibr">48</xref>]. DCA has been shown to induce autophagy instead of inhibiting it. In a study conducted by Lin and colleagues on colorectal cancer cell lines, it was determined that while DCA caused a G1 phase cycle arrest and reduced the growth of HCT116 WT, HT29, and PC3 cell lines, there was an overexpression of LC3B II, which is an indicator of autophagy. This was confirmed via electron microscopy, which revealed double-membrane autophagosomes in all the groups that underwent DCA administration [<xref rid="B47-medsci-13-00047" ref-type="bibr">47</xref>]. The DCA-induced induction of autophagy was found to be mediated by the generation of ROS, the inhibition of the mammalian targets of rapamycin (mTOR), lactate excretion, the pyruvate-to-lactate exchange rate (k<sub>PL</sub>), and increased NAD+ and ratio of NAD+/NADH. In an in vivo study, DCA decreased the growth of HT29 tumor xenografts, which was mediated via reduced k<sub>PL</sub> and increased autophagy [<xref rid="B47-medsci-13-00047" ref-type="bibr">47</xref>]. Nevertheless, DCA has also been shown to inhibit autophagy in A549 and H1975 NSCLC cell lines [<xref rid="B48-medsci-13-00047" ref-type="bibr">48</xref>]. By examining the essential autophagy proteins, LC3 and sequestosome (SQSTM; p62), after DCA administration, Lu and colleagues found that LC3 decreased while p62 levels increased, both of which are hallmarks of autophagy inhibition [<xref rid="B48-medsci-13-00047" ref-type="bibr">48</xref>]. In vivo studies have demonstrated that DCA inhibits the growth of A549 and H1975 tumor xenografts and enhances the survival of tumor-bearing nude mice [<xref rid="B48-medsci-13-00047" ref-type="bibr">48</xref>].</p><p>Despite its promising anticancer properties, environmental exposure to DCA has been reported to cause lung irritation, cough, shortness of breath, and bronchitis [<xref rid="B49-medsci-13-00047" ref-type="bibr">49</xref>]. However, the most clinically limiting side effect of DCA is peripheral neuropathy. Chronic DCA exposure is suspected to cause oxidative stress in Schwann cells due to glycolytically mediated ROS generation. DCA-induced oxidative stress often results from reactive molecules, which form DNA/protein adducts from interference with amino acid catabolism and heme synthesis [<xref rid="B50-medsci-13-00047" ref-type="bibr">50</xref>]. Alongside potentially degrading Schwann cells, DCA diminishes myelin-associated proteins, indicating that its effects on the nervous system could also be the result of demyelinating neurons [<xref rid="B51-medsci-13-00047" ref-type="bibr">51</xref>]. Thus, the careful consideration of the optimal dose of DCA is needed to not only prevent its side effects but also to exploit its ability to improve the efficacy of other therapeutic agents.</p><p>Furthermore, DCA exerts synergistic potential with the most widely used chemotherapy agent, paclitaxel, on NSCLC cells. Studies by Lu and colleagues demonstrated that DCA enhanced the paclitaxel-induced inhibition of in vitro proliferation and autophagy of A549 and H1975 cell lines, as well as tumor growth and increased mice survival, indicating that DCA enhances chemotherapy efficacy [<xref rid="B48-medsci-13-00047" ref-type="bibr">48</xref>]. Along similar lines, studies by Sun and colleagues have found that PDK2 inhibition via siRNA-induced downregulation was able to disrupt Warburg metabolism and resensitize paclitaxel-resistant A549-R cells to paclitaxel [<xref rid="B52-medsci-13-00047" ref-type="bibr">52</xref>]. The combination of paclitaxel with the PDK2 inhibitor DCA resulted in the inhibition of the viability of A549-R cells in a synergistic manner. These findings indicate that the antiglycolysis mechanisms of DCA allow it to synergize with paclitaxel [<xref rid="B52-medsci-13-00047" ref-type="bibr">52</xref>].</p><p>Platinum-based chemotherapies, such as cisplatin, are commonly used to treat metastatic NSCLC. DCA is a strong contender as an anticancer drug for NSCLC, in part because of its ability to synergize with cisplatin. Alongside its ability to shift the Warburg effect, DCA has been shown to synergistically inhibit cervical cancer (HeLa) cells in combination with cisplatin in vitro [<xref rid="B53-medsci-13-00047" ref-type="bibr">53</xref>]. Xie and colleagues suggested that the unique metabolic action expressed by DCA, such as shifting HeLa cells&#x02019; metabolism from aerobic glycolysis to glucose oxidation, results in decreased mitochondrial membrane potential and increases the susceptibility of apoptosis-sensitized HeLa cells to the cytotoxic effects of cisplatin [<xref rid="B53-medsci-13-00047" ref-type="bibr">53</xref>]. Moreover, Garon and colleagues determined the effects of DCA with or without cisplatin and docetaxel in NSCLC cell lines under normoxic and hypoxic conditions [<xref rid="B54-medsci-13-00047" ref-type="bibr">54</xref>]. The data demonstrated the limited sensitivity of the DCA in all 54 tested NSCLC cell lines. Under hypoxic conditions, the DCA and cisplatin combination resulted in the inhibition of cell growth of a few cell lines (e.g., A427 and HCC-827). However, this combination did not show any synergistic effect on the SKLU-1 and A549 cell lines. In contrast, the DCA and docetaxel combination did not exert a synergistic effect [<xref rid="B54-medsci-13-00047" ref-type="bibr">54</xref>]. In addition, a clinical trial conducted on seven patients suggested that oral DCA did not benefit previously treated NSCLC patients. The limitation of this study was the number of recruited patients. Thus, this warrants further studies to explore the efficacy of DCA as a sensitizing agent with combination therapy [<xref rid="B54-medsci-13-00047" ref-type="bibr">54</xref>].</p><p>While most DCA anticancer mechanisms are involved in limiting growth and proliferation, they can also directly promote cell suicide. For instance, an apoptosis-promoting enzyme, caspase 3/7, is released upon high doses of DCA. These anti-proliferative effects are best attributed to the inhibition of pyruvate. Alongside its effects on glucose consumption, DCA was also observed to have an impact on angiogenesis, which ensures the supply of oxygen and nutrients to cancer cells [<xref rid="B55-medsci-13-00047" ref-type="bibr">55</xref>]. This property was investigated using human umbilical vein endothelial cells (HUVECs) capillary structures [<xref rid="B55-medsci-13-00047" ref-type="bibr">55</xref>]. In addition, DCA was found to enhance cisplatin chemotherapy, as well as gefitinib- or erlotinib-targeted therapy-induced decreased cell viability. Importantly, an in vivo study demonstrated the inhibitory effects of DCA on tumor xenograft growth in a chick embryo chorioallantoic membrane model, as well as on LNM35 tumor xenografts in nude mice [<xref rid="B55-medsci-13-00047" ref-type="bibr">55</xref>]. The limitations of that study included the inability of DCA to inhibit in vitro cell migration and invasion, as well as the incidence/growth of lymph node metastasis in vivo [<xref rid="B55-medsci-13-00047" ref-type="bibr">55</xref>]. Overall, the findings indicated that the efficacy of DCA is due to its ability to disrupt angiogenesis [<xref rid="B55-medsci-13-00047" ref-type="bibr">55</xref>]. Thus, a reduction in angiogenesis is another anti-proliferative mechanism of DCA and is likely linked to its ability to reduce lactate concentration via PDK inhibition [<xref rid="B56-medsci-13-00047" ref-type="bibr">56</xref>,<xref rid="B57-medsci-13-00047" ref-type="bibr">57</xref>].</p><p>In addition to synergizing with cisplatin, DCA has also been shown to be a significant contender for combination therapy with TKIs, targeted therapeutics that have become a standard treatment for NSCLC [<xref rid="B58-medsci-13-00047" ref-type="bibr">58</xref>]. Together with erlotinib or gefitinib, DCA has been shown to decrease the viability and cell proliferation of, and promote apoptosis in, EGFR-mutant, NCI-H1975, and NCI-H1650, but not in A549 or NCI-H460 NSCLC cell lines, which do not harbor EGFR mutations. In this study, Yang and colleagues provided compelling evidence that in EGFR-mutant (not EGFR wild-type) cell lines, erlotinib or gefitinib suppresses the activation of EGFR, along with AKT and extracellular signal-regulated kinase 1/2 (ERK1/2), two key proteins that are present in the downstream of EGFR signaling but have no effect on PDK activation. In contrast, DCA inhibited PDH activation in EGFR-mutant cells, but did not exert any effects on EGFR, AKT, or ERK1/2 phosphorylation [<xref rid="B58-medsci-13-00047" ref-type="bibr">58</xref>]. On the other hand, in EGFR wild-type cells, erlotinib or gefitinib did not exert any effect on the activation of EGFR, AKT, or ERK1/2, whereas DCA inhibited PDH activation. Similarly, the combination of DCA with either erlotinib or gefitinib had pronounced effects on the inhibition of EGFR, AKT, and ERK1/2 phosphorylation, but did not affect PDH phosphorylation in EGFR-mutant cells or vice versa, indicating that DCA and EGFR TKIs exert independent functions in targeting signaling cascades [<xref rid="B58-medsci-13-00047" ref-type="bibr">58</xref>].</p><p>Additionally, the anti-autophagic property of DCA has been shown to have a synergistic effect with another traditional chemotherapy agent, doxorubicin, which is commonly used to treat breast cancer [<xref rid="B59-medsci-13-00047" ref-type="bibr">59</xref>]. Unfortunately, doxorubicin can be a potent autophagy inducer, including in the MDA-MB-231 breast cancer cell line. To that end, the authors of that study demonstrated that the previously known autophagy inhibition mechanisms exhibited by DCA were able to desensitize doxorubicin-resistant cells and enhance its cytotoxic effects [<xref rid="B59-medsci-13-00047" ref-type="bibr">59</xref>]. This effect was further tested in vivo in mice, where DCA was shown to increase the anticancer effects of doxorubicin. These studies highlight the ability of DCA to synergize with traditional NSCLC agents, often sensitizing their cytotoxic capabilities and combating resistance mechanisms [<xref rid="B59-medsci-13-00047" ref-type="bibr">59</xref>].</p><p>Another chemotherapy agent that DCA has been shown to be synergistic with is capecitabine. This combination is of particular interest because, like DCA, capecitabine has a high oral bioavailability. To that end, studies by Zheng and colleagues demonstrated that despite having little effect as a monotherapy, DCA significantly increased the antitumor effects of capecitabine in vivo in B-16 mouse allograft and A549 mouse xenograft models [<xref rid="B60-medsci-13-00047" ref-type="bibr">60</xref>]. This effect was mediated by sensitizing apoptosis via remarkably increasing the cleavage of pro-caspases 8, 9, and 3, resulting in a reduced effective dose of capecitabine [<xref rid="B60-medsci-13-00047" ref-type="bibr">60</xref>].</p><p>In addition, DCA has been shown to synergize with non-pharmacological cancer treatments as well. De Mey and colleagues investigated how DCA&#x02019;s mechanisms can sensitize breast cancer cells to hypoxic radiotherapy treatment [<xref rid="B61-medsci-13-00047" ref-type="bibr">61</xref>]. They hypothesized that under hypoxic conditions, pyruvate delivery into the mitochondria causes an upregulation of ROS levels, which radio-sensitizes cancer cells. This was partially confirmed by ROS-induced apoptosis and sensitivity in vivo [<xref rid="B61-medsci-13-00047" ref-type="bibr">61</xref>]. Cook and colleagues showed how the metabolic actions of DCA affect high-grade glioma (HGG) cells [<xref rid="B62-medsci-13-00047" ref-type="bibr">62</xref>]. Along with upregulating glycolysis, HGG cells are capable of utilizing glucose coupled with OXPHOS. HGG tissue is highly heterogeneous and OXPHOS is a contributor to chemo/radiotherapy resistance in this type of tumor. These factors put the efficacy of DCA as an anticancer agent into question. However, even at low concentrations, DCA was shown to radio-sensitize HGGs and induce apoptosis via ROS-induced DNA damage, cell cycle arrest, and an improved in vivo survival rate [<xref rid="B62-medsci-13-00047" ref-type="bibr">62</xref>]. These effects imply that even in highly heterogeneous tissues, DCA still functions as a metabolic modulator.</p><p>DCA has also been shown to have anticancer synergies with various non-traditional agents, the most prominent of which is metformin. Metformin, like DCA, is a metabolic modulator that has a clinical history of being used to treat diabetes and hyperglycemia. As discussed in the introductory paragraphs, antimetabolites that interrupt glycolysis have strong potential as anticancer therapeutics because of their possible effects on Warburg metabolism. Li and colleagues found that DCA and metformin were able to synergistically inhibit the growth of and induce apoptosis in ovarian cancer cells [<xref rid="B63-medsci-13-00047" ref-type="bibr">63</xref>]. Interestingly, it was found that while metformin sensitized DCA cytotoxicity via reducing DCA-induced anti-apoptotic Mcl-1 protein expression and protective autophagy, DCA sensitized metformin&#x02019;s effects via decreasing metformin-induced glucose consumption and lactate accumulation [<xref rid="B63-medsci-13-00047" ref-type="bibr">63</xref>]. The in vivo studies complemented the in vitro findings that DCA and metformin inhibit the growth of tumor xenografts in nude mice in a synergistic manner, indicating the promising efficacy of this combination against ovarian cancer [<xref rid="B63-medsci-13-00047" ref-type="bibr">63</xref>]. Similar results were achieved by Haugrud and colleagues, who demonstrated that DCA and metformin&#x02019;s combination synergistically induces cell death via caspase-dependent apoptosis in MCF7 and T47D human breast cancer cell lines [<xref rid="B64-medsci-13-00047" ref-type="bibr">64</xref>]. Mechanistically, this effect involves oxidative damage via the inhibition of PDK1, with the simultaneous attenuation of metformin-induced lactate production [<xref rid="B64-medsci-13-00047" ref-type="bibr">64</xref>]. These findings indicate that DCA and metformin&#x02019;s combination could be explored as a promising therapy for breast cancer.</p><p>Metformin, however, is not the only non-traditional anticancer agent that DCA has been shown to be synergistic with. PX-478 is a small molecule that interferes with the transcription and translation of hypoxia-inducible factor-1&#x003b1; (HIF-1&#x003b1;) and leads to the diminished deubiquitinating of HIF-1&#x003b1;. Parczyk and colleagues determined that DCA and PX-478 have potential as a combination therapy for a variety of cancer cell lines (colorectal, lung, breast, cervical, liver, and brain) [<xref rid="B65-medsci-13-00047" ref-type="bibr">65</xref>]. The suggested mechanisms include a strengthened inhibition of HIF-1&#x003b1; and increased ROS-mediated apoptosis of mitochondria through the targeting of PDKs. While DCA suppresses PDK-1, HIF-1&#x003b1; increases PDK-1 expression. Thus, PX-478 reinforces the primary effect of DCA indirectly, thereby synergistically increasing ROS production when combined with DCA [<xref rid="B65-medsci-13-00047" ref-type="bibr">65</xref>].</p><p>Another compound that DCA has been shown to have a strong synergism with is ivermectin. In a case report by Ishiguro and colleagues, DCA in combination with ivermectin, tamoxifen, and omeprazole was shown to relieve the symptoms of cancer progression [<xref rid="B66-medsci-13-00047" ref-type="bibr">66</xref>]. Mechanistically, tamoxifen induces caspase-dependent cell growth inhibition and omeprazole enhances the antitumor effects of DCA, while ivermectin, an antiparasitic agent commonly used in veterinary medicine, exhibits growth-inhibitory effects on cancer cells via its ability to cause mitochondrial dysfunction and oxidative damage [<xref rid="B66-medsci-13-00047" ref-type="bibr">66</xref>]. Given that cancer-related pain is a significant source of morbidity and decreases the quality of life of patients, by exhibiting the same antitumor mechanisms, these agents have been shown to relieve the advanced symptoms accompanying cancer progression, including pain [<xref rid="B66-medsci-13-00047" ref-type="bibr">66</xref>]. A schematic representation of the synergistic mechanisms of DCA, both alone and with other anticancer agents, is shown in <xref rid="medsci-13-00047-f001" ref-type="fig">Figure 1</xref>. A summary of the in vitro and in vivo studies demonstrating the effects and mechanisms of DCA alone, as well as its synergy with other anticancer agents in various cancer models, is given in <xref rid="medsci-13-00047-t001" ref-type="table">Table 1</xref>.
<table-wrap position="anchor" id="medsci-13-00047-t001"><object-id pub-id-type="pii">medsci-13-00047-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of in vitro and/or in vivo studies of DCA alone or its combination with other therapeutic agent(s).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA</td><td align="center" valign="middle" rowspan="1" colspan="1">A549, H1299</td><td align="center" valign="middle" rowspan="1" colspan="1">Lactate <break/>production/<break/>glucose <break/>consumption</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA decreases lactate production and glucose consumption.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B42-medsci-13-00047" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA</td><td align="center" valign="middle" rowspan="1" colspan="1">HCT116 WT, HT29, PC3</td><td align="center" valign="middle" rowspan="1" colspan="1">Autophagy (LC3B ll protein), mTOR, lactate excretion, tumor growth</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA induces autophagy in colorectal cell lines via inducing ROS generation and inhibiting mTOR and lactate excretion.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B47-medsci-13-00047" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA, paclitaxel</td><td align="center" valign="middle" rowspan="1" colspan="1">A549, H1975</td><td align="center" valign="middle" rowspan="1" colspan="1">Autophagy (LC3 and p62 proteins), tumor growth</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA inhibits autophagy, decreases cell proliferation and tumor growth, and increases mice survival.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B48-medsci-13-00047" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA, paclitaxel</td><td align="center" valign="middle" rowspan="1" colspan="1">A549-R</td><td align="center" valign="middle" rowspan="1" colspan="1">PDK2</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA resensitizes paclitaxel-resistant cells through PDK2 inhibition and siRNA-mediated downregulation.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B52-medsci-13-00047" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA, cisplatin</td><td align="center" valign="middle" rowspan="1" colspan="1">HeLa</td><td align="center" valign="middle" rowspan="1" colspan="1">Glucose metabolism</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA is able to shift glucose metabolism to sensitize HeLa cells and exert synergy with cisplatin.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B53-medsci-13-00047" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA, cisplatin, decetaxel</td><td align="center" valign="middle" rowspan="1" colspan="1">54 NSCLC cells</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">Under hypoxic conditions, DCA and cisplatin (not docetaxel) combination enhances the sensitivity of a few NSCLC cell lines.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B54-medsci-13-00047" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA + cisplatin/<break/>gefitinib or erlotinib</td><td align="center" valign="middle" rowspan="1" colspan="1">A549, LNM35</td><td align="center" valign="middle" rowspan="1" colspan="1">Cell viability, <break/>angiogenesis, tumor growth</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA decreases cell viability, disrupts angiogenesis, and reduces tumor growth.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B55-medsci-13-00047" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA, gefitinib, erlotinib</td><td align="center" valign="middle" rowspan="1" colspan="1">NCI-H1975, <break/>NCI-H1650, A549, NCI-H460</td><td align="center" valign="middle" rowspan="1" colspan="1">EGFR, AKT, ERK1/2, PDH signaling</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA in combination with gefitinib or erlotinib significantly inhibits the cell viability, promotes the apoptosis, and suppresses the activation of EGFR, AKT, and ERK1/2 signaling in EGFR-mutant NSCLC cell lines.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B58-medsci-13-00047" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA, doxorubicin</td><td align="center" valign="middle" rowspan="1" colspan="1">MDA-MB-231</td><td align="center" valign="middle" rowspan="1" colspan="1">Autophagy</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA sensitizes doxorubicin-induced cell death via autophagy inhibition, and its mechanism resensitizes doxorubicin-resistant cells and enhances the chemotherapeutic effect.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B59-medsci-13-00047" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA, capecitabine</td><td align="center" valign="middle" rowspan="1" colspan="1">A549, B-16</td><td align="center" valign="middle" rowspan="1" colspan="1">Caspases/<break/>apoptosis</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA enhances the cytotoxic effects of capecitabine by promoting the release of caspases 3, 8, and 9.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B60-medsci-13-00047" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA, metformin</td><td align="center" valign="middle" rowspan="1" colspan="1">SKOV3, OVCAR3</td><td align="center" valign="middle" rowspan="1" colspan="1">Mcl-1, Warburg effect, glycolysis, autophagy</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA and metformin&#x02019;s combination synergistically inhibits cell viability via inducing apoptosis, and reduces the growth of tumor xenografts.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B63-medsci-13-00047" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DCA, metformin<break/>DCA, PX-478</td><td align="center" valign="middle" rowspan="1" colspan="1">MCF7, T47D<break/>MCF-7, <break/>MDA-MB-231, A549, H441, HEK-293, U251, HeLa, HEPG2, HT-29</td><td align="center" valign="middle" rowspan="1" colspan="1">PDK1, glycolysis <break/>HIF-1&#x003b1;, PDK1</td><td align="center" valign="middle" rowspan="1" colspan="1">DCA and metformin&#x02019;s combination synergistically induces cell death and oxidative damage via PDK1 inhibition. <break/>DCA synergistically inhibits cancer cell growth with HIF-1&#x003b1; inhibitor PX-478 via inducing ROS-mediated apoptosis.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B64-medsci-13-00047" ref-type="bibr">64</xref>,<xref rid="B65-medsci-13-00047" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCA, ivermectin, omeprazole, tamoxifen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer progression symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCA in combination with ivermectin, omeprazole, and tamoxifen relieves metastatic cancer-induced pain in patients.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-medsci-13-00047" ref-type="bibr">66</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">DCA</italic>, dichloroacetate; <italic toggle="yes">LC3</italic>, microtubule-associated protein 1 light chain 3; <italic toggle="yes">LC3B</italic>, LC3 isoform B; p62, sequestosome-1; mTOR, mammalian target of rapamycin; <italic toggle="yes">AKT</italic>, Ak strain transforming protein kinase B; <italic toggle="yes">ERK1/2</italic>, extracellular signal-related protein&#x02013;serine/threonine kinases 1 and 2; <italic toggle="yes">PDK2</italic>, pyruvate dehydrogenase kinase 2; <italic toggle="yes">EGFR</italic>, epidermal growth factor receptor; <italic toggle="yes">HIF-1&#x003b1;</italic>, hypoxia-inducible factor 1-alpha.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="sec5-medsci-13-00047"><title>5. Pharmacology of Salinomycin</title><p>Salinomycin (SAL) is a polyether ionophore with an extended history of anti-microbial usage. It belongs to a selection of naturally occurring molecules comprising numerous cyclic ether groups [<xref rid="B67-medsci-13-00047" ref-type="bibr">67</xref>,<xref rid="B68-medsci-13-00047" ref-type="bibr">68</xref>]. Moreover, a characteristic feature of the SAL structure is the presence of a unique tricyclic 6-6-5 bis-spirochetal ring system with cis isomerism, which stiffens the whole compound [<xref rid="B67-medsci-13-00047" ref-type="bibr">67</xref>,<xref rid="B68-medsci-13-00047" ref-type="bibr">68</xref>]. It was isolated from Streptomyces albus, a species of bacterium, and produced by tank fermentation technology [<xref rid="B69-medsci-13-00047" ref-type="bibr">69</xref>].</p><p>Ionophores are a subtype of anti-microbials that promote the transport of ions across the cell membrane. There are two different groups of ionophores: mobile carriers that bind ions to form lipid-soluble complexes and channel-forming compounds. Mobile carriers, such as SAL, are classified as carboxylic (neutral-charged) ionophores. By being a carboxylic transporter, it can ease the ion flux through to the cytoplasmic and mitochondrial membranes [<xref rid="B69-medsci-13-00047" ref-type="bibr">69</xref>]. SAL and other antibiotics of its kind have been routinely added to the diets of poultry and livestock to prevent the spread of bacterial infections. However, SAL has been shown to be a broad-spectrum anti-microbial agent that can be used to treat more bacterial species. In addition, SAL is strongly antiparasitic, since it is used to effectively treat the spread of coccidiosis, a parasitic infection that can cause major economic loss in poultry farming, and has been shown to be able to eliminate malaria in vitro [<xref rid="B70-medsci-13-00047" ref-type="bibr">70</xref>]. Alongside its antibacterial and antiparasitic uses, SAL has also been proven to possess properties that are anti-viral, antifungal, and even anti-inflammatory [<xref rid="B70-medsci-13-00047" ref-type="bibr">70</xref>,<xref rid="B71-medsci-13-00047" ref-type="bibr">71</xref>,<xref rid="B72-medsci-13-00047" ref-type="bibr">72</xref>,<xref rid="B73-medsci-13-00047" ref-type="bibr">73</xref>].</p><p>The most plausible explanation for this wide range of anti-microbial abilities lies within its proposed mechanisms. SAL has been shown to inhibit oxidative mitochondrial metabolism via ionophoric action. Via a complexation reaction, SAL disrupts the sodium/potassium ion balance across mitochondrial and cell membranes by the rapid efflux of K<sup>+</sup>. The ion reactions catalyzed by SAL lead to mass-scale apoptosis [<xref rid="B74-medsci-13-00047" ref-type="bibr">74</xref>]. However, redirecting the flux of K<sup>+</sup> is only one of SAL&#x02019;s mechanisms that cause cell death. Notably, ferroptosis is a unique form of anti-cellular activity that is distinct from apoptosis and necrosis; it is instead dependent on autophagy. Autophagy causes the degradation of the iron storage protein, ferritin, which consequently releases more Fe<sup>2+</sup>, resulting in oxidative injury via a Fenton reaction. Another feature of ferroptosis is an overwhelming, iron-dependent accumulation of lethal lipids and ROS. SAL and its derivatives prevent the movement of iron from the lumen to the cytosol, triggering an iron-depletion reaction that is characterized by the rapid degradation of ferritin [<xref rid="B75-medsci-13-00047" ref-type="bibr">75</xref>]. Ironomycin, a more potent derivative of SAL, has been found to physically accumulate in lysosomes, which disrupts their functioning by an excessive overloading of iron [<xref rid="B76-medsci-13-00047" ref-type="bibr">76</xref>,<xref rid="B77-medsci-13-00047" ref-type="bibr">77</xref>,<xref rid="B78-medsci-13-00047" ref-type="bibr">78</xref>].</p></sec><sec id="sec6-medsci-13-00047"><title>6. SAL as an Anticancer Agent and Its Synergy with Other Therapeutic Agents</title><p>Cancer stem cells (CSCs) are one of the major challenges in the treatment of recurrence and metastasis. CSCs make up 2&#x02013;5% of cells within a tumor matrix and have a variety of unique properties, which include the ability to asymmetrically divide, differentiate, and self-renew, alongside an inherent resistance to therapy [<xref rid="B79-medsci-13-00047" ref-type="bibr">79</xref>,<xref rid="B80-medsci-13-00047" ref-type="bibr">80</xref>,<xref rid="B81-medsci-13-00047" ref-type="bibr">81</xref>]. CSCs play a pivotal role in cancer metastasis and their increased presence is strongly correlated with poor patient outcomes [<xref rid="B81-medsci-13-00047" ref-type="bibr">81</xref>,<xref rid="B82-medsci-13-00047" ref-type="bibr">82</xref>]. By only targeting non-CSCs, traditional chemotherapy agents provide more space for CSCs to evolve into a more aggressive malignancy [<xref rid="B83-medsci-13-00047" ref-type="bibr">83</xref>]. The challenge of treating CSCs makes it exigent to find an agent that can selectively target them. SAL has been shown to selectively target CSCs in vitro and in vivo, but its mode of action is not fully understood. However, the high anti-CSC bioactivity of this antibiotic is most likely linked to its ability to act as complex cations, which results in changes in the ion gradient and intracellular ph. Its proposed mechanisms, such as changes in the ion gradient, could result in injury to CSC mitochondria because they need an H<sup>+</sup> ion gradient to generate enough ATP via OXPHOS, while changes in the pH could cause the denaturation of key proteins in mitochondrial function [<xref rid="B83-medsci-13-00047" ref-type="bibr">83</xref>].</p><p>Using an active fluorescent SAL conjugate, it has also been shown that the molecular initiating event leading to a selective reduction in the proportion of CSCs after SAL treatment is strictly connected to a net outflux of Ca<sup>2+</sup> cations from the endoplasmic reticulum (ER) because of the SAL-mediated alkali&#x02013;metal ion transport across the ER membrane. A chemical library screened by Gupta and colleagues demonstrated that SAL can decrease the percentage of CD44-high/CD24-low breast CSCs by 20-fold [<xref rid="B84-medsci-13-00047" ref-type="bibr">84</xref>]. While SAL has been shown to be effective against breast, colorectal, and circulatory cancers in these previous studies, the CSC targeting mechanism seen in SAL is not entirely understood [<xref rid="B84-medsci-13-00047" ref-type="bibr">84</xref>,<xref rid="B85-medsci-13-00047" ref-type="bibr">85</xref>,<xref rid="B86-medsci-13-00047" ref-type="bibr">86</xref>,<xref rid="B87-medsci-13-00047" ref-type="bibr">87</xref>,<xref rid="B88-medsci-13-00047" ref-type="bibr">88</xref>,<xref rid="B89-medsci-13-00047" ref-type="bibr">89</xref>]. Another proposed mode of action is connected to its effects on the Wnt/beta-catenin transduction pathway [<xref rid="B89-medsci-13-00047" ref-type="bibr">89</xref>]. The Wnt oncogene and its signaling component, beta-catenin, was confirmed by Zhang and colleagues to be significantly transcribed in lung cancer cells, and SAL was one of the compounds used to inhibit the Wingless-related integration site pathway (Wnt) signaling in their study [<xref rid="B90-medsci-13-00047" ref-type="bibr">90</xref>]. By suppressing Wnt through interfering with beta-catenin/CREB-binding protein transcriptional complexes, SAL was shown to be able to significantly reduce cancer cell stemness within lung cancer cell lines. Along similar lines, SAL was shown to suppress the stemness of liver cancer stem cells (LCSCs) enriched from MHCC97H cells via the inhibition of Wnt/beta-catenin signaling [<xref rid="B91-medsci-13-00047" ref-type="bibr">91</xref>].</p><p>Eliminating CSCs is far from the only anticancer property that has been observed for SAL. SAL has also been shown to suppress the epithelial&#x02013;mesenchymal transition (EMT) as well as transforming growth factors (TGFs). EMT is a process that is pivotal to metastasis. Epithelial-like cancer cells are changed, in part, by the transforming growth factor &#x003b2; (TGF&#x003b2;) into mesenchymal-adjacent cells. This process promotes their invasion into other tissues. In a study conducted by Koeck and colleagues, SAL was shown to inhibit the EMT-inducing effect of TGF&#x003b2; when used at the lower dose, while the higher dose further enhanced the mesenchymal phenotype in HCC4006 cells [<xref rid="B92-medsci-13-00047" ref-type="bibr">92</xref>]. In A549 and HCC4006 cells, cell migration was decreased. In the A549 cells, however, it was noted that EMT markers, such as E-cadherin, were downregulated and vimentin was upregulated, leading the researchers to hypothesize that SAL may inhibit cell migration and influence the TGF&#x003b2;-related EMT by interfering with different signaling pathways [<xref rid="B92-medsci-13-00047" ref-type="bibr">92</xref>]. This was further confirmed by Hwang and colleagues when they discovered that SAL inhibits the TGF-&#x003b2;1-induced EMT through the AMPK/SIRT1 signaling pathways in both A549 and H460 cell lines [<xref rid="B93-medsci-13-00047" ref-type="bibr">93</xref>]. Researchers proposed that these two proteins act synergistically with SAL to inhibit TGF-&#x003b2;1 [<xref rid="B93-medsci-13-00047" ref-type="bibr">93</xref>].</p><p>SAL has been shown to have multiple apoptosis mechanisms. A study by Arafat and colleagues demonstrated that SAL inhibits the viability of A549 and LNM35 NSCLC cells in a dose- and time-dependent manner via inducing caspase 3/7-mediated apoptosis [<xref rid="B94-medsci-13-00047" ref-type="bibr">94</xref>]. Moreover, decreased cell migration and invasion, as well as colony formation, were observed during SAL treatment. These effects were found to be mediated via an SAL-induced increased expression of the pro-apoptotic protein, NSAID-activated gene (NAG-1), a member of the TGF-&#x003b2; super-family, also known as macrophage inhibitory cytokine (MIC-1) and growth and differentiation factor-15 (GDF-15) [<xref rid="B94-medsci-13-00047" ref-type="bibr">94</xref>]. Another apoptotic mechanism is the induction of intracellular ROS, which can best be attributed to its ionophoric action. Kim and colleagues demonstrated that SAL inhibits the viability of PC-3, LNCaP, and DU-145 prostate cancer cell lines in a dose- and time-dependent manner, with non-malignant RWPE-1 prostate cells being less sensitive [<xref rid="B95-medsci-13-00047" ref-type="bibr">95</xref>]. Using PC-3 cells, it was observed that SAL triggers apoptosis by elevating intracellular ROS levels, leading to the translocation of Bax protein to the mitochondria, cytochrome c (Cytc) release, and the activation of caspase-3 [<xref rid="B95-medsci-13-00047" ref-type="bibr">95</xref>]. Another prominent apoptosis mechanism is the induction of autophagy. Studies conducted by Li and colleagues confirmed that SAL induces autophagic flux in A549, Calu-1, and H157 NSCLC cell lines and proposed that this autophagy induction was due to endoplasmic reticulum (ER) stress [<xref rid="B96-medsci-13-00047" ref-type="bibr">96</xref>]. SAL was observed to upregulate ER stress-related proteins in a time-/dose-dependent manner, which was found to be mediated via the ATF4-DDIT3/CHOP-TRIB3-AKT1-MTOR axis. However, the autophagic response caused by SAL has been shown to counteract its apoptotic effects [<xref rid="B96-medsci-13-00047" ref-type="bibr">96</xref>]. This similar effect was also observed by Jangamreddy and colleagues alongside the mitophagy and hyperpolarization of mitochondria in prostate and breast carcinoma cell lines, and to a lesser extent in human normal dermal fibroblasts [<xref rid="B97-medsci-13-00047" ref-type="bibr">97</xref>]. This effect was due to autophagy being a cell protective mechanism. However, autophagic flux can be counteracted by inhibiting agents, such as SAL, which have been shown to possess potential anti-resistance properties as well, alongside their ability to selectively target CSCs [<xref rid="B98-medsci-13-00047" ref-type="bibr">98</xref>]. Studies by Fuchs and colleagues observed that SAL induced cell death in multiple apoptosis-resistant cancer cell lines, but not in normal healthy human cells [<xref rid="B99-medsci-13-00047" ref-type="bibr">99</xref>]. This effect was more enhanced in human Molt-4 CD4+ T-cell leukemia cells.</p><p>Despite its promising anticancer properties, SAL causes several adverse effects, such as neurotoxicity [<xref rid="B100-medsci-13-00047" ref-type="bibr">100</xref>]. SAL was shown to disrupt Na+ and Ca<sub>2</sub>+ homeostasis in root ganglia neurons. The ionophoric action of SAL then results in calpain/caspase-mediated cell death [<xref rid="B100-medsci-13-00047" ref-type="bibr">100</xref>]. In in vivo studies, SAL administration has been shown to cause paralysis of the extremities and reproductive damage in mice [<xref rid="B101-medsci-13-00047" ref-type="bibr">101</xref>]. The reproductive damage consisted of the disruption of spermatogenesis and the shrinking of testes. Alongside decreasing the rate of fertility in male mice, SAL also reduced the rate of pregnancy in female mice [<xref rid="B101-medsci-13-00047" ref-type="bibr">101</xref>]. Thus, careful consideration of the optimal doses of SAL is needed to not only prevent its side effects but to also exploit its ability to improve the efficacy of other therapeutic agents.</p><p>In addition to its use as a monotherapy, SAL has also been shown to exert synergy with other therapeutics. In a study conducted by Xiao and colleagues, NSCLC cell lines were treated with SAL and metformin [<xref rid="B86-medsci-13-00047" ref-type="bibr">86</xref>]. The findings indicated that not only did the combination of SAL and metformin inhibit cell viability, but upon microscopic examination, they revealed a substantial increase in cell death and a subsequent decrease in cell density. These effects were found to be mediated by the inhibition of AKT, ERK1/2, mTOR, and the downstream signaling cascade p70 s6K, regardless of the EGFR, KRAS, ALK, and LKB1 status of the cell lines. A particularly important technique in this study was the use of alveospheres that stimulated CSC-modulated tumor heterogeneity [<xref rid="B86-medsci-13-00047" ref-type="bibr">86</xref>]. It was revealed that the exposure of alveospheres of various NSCLC cell types to the same concentrations of metformin turned out to be less effective than in 2D cultures, whereas co-exposure to SAL significantly enhanced metformin efficiency [<xref rid="B86-medsci-13-00047" ref-type="bibr">86</xref>].</p><p>An additional oncogenic pathway that SAL disrupts is constitutively active AKT (AKT-CA), through the downregulation of thymidylate synthase (TS) [<xref rid="B102-medsci-13-00047" ref-type="bibr">102</xref>]. Thymidylate synthase is a key enzyme in the pyrimidine salvage pathway, and its increased expression is positively associated with chemotherapy resistance [<xref rid="B102-medsci-13-00047" ref-type="bibr">102</xref>]. According to Tung and colleagues, SAL was able to exert a combined cytotoxic effect with erlotinib by inhibiting TS through siRNA-mediated silencing and subsequent AKT inactivation [<xref rid="B102-medsci-13-00047" ref-type="bibr">102</xref>]. Similar results were observed by Ko and colleagues, who showed that SAL could sensitize NSCLC cells to cisplatin [<xref rid="B103-medsci-13-00047" ref-type="bibr">103</xref>]. Agents that have been reportedly desensitized due to the presence of TS include erlotinib and platinum-based therapies, such as cisplatin, both of which are used in the treatment of advanced NSCLC [<xref rid="B103-medsci-13-00047" ref-type="bibr">103</xref>,<xref rid="B104-medsci-13-00047" ref-type="bibr">104</xref>,<xref rid="B105-medsci-13-00047" ref-type="bibr">105</xref>]. Along similar lines, a study by Michalak and colleagues generated cisplatin-resistant ovarian cancer cell lines that exhibited an elevated expression of the genes related to drug transporters [<xref rid="B106-medsci-13-00047" ref-type="bibr">106</xref>]. In this study, the authors demonstrated that SAL, in combination with other cytostatic agents, such as 5-fluorouracil (5FU) and gemcitabine, was able to resensitize ovarian cancer cell lines to cisplatin [<xref rid="B106-medsci-13-00047" ref-type="bibr">106</xref>].</p><p>Moreover, SAL has also been shown to be a synergist with TKIs, such as gefitinib. A study by Zou and colleagues determined that SAL, in combination with gefitinib, was able to successfully induce apoptosis in gefitinib-resistant colorectal cancer cell lines regardless of their EGFR and KRAS status [<xref rid="B107-medsci-13-00047" ref-type="bibr">107</xref>]. These effects were found to be mediated through the reduced activation of AKT, the loss of lysosomal membrane potential and mitochondrial membrane potential, and ROS production [<xref rid="B107-medsci-13-00047" ref-type="bibr">107</xref>]. Additionally, it was also discovered that SAL and gefitinib overcame gefitinib resistance in Ras-overexpressing cells by the same mechanisms. Similar effects were also observed in vivo in mouse xenograft models, demonstrating that SAL and gefitinib&#x02019;s combination sensitized gefitinib-resistant tumor xenografts to gefitinib [<xref rid="B107-medsci-13-00047" ref-type="bibr">107</xref>]. A schematic representation of the mechanisms of SAL, alone and in combination with other agents, is shown in <xref rid="medsci-13-00047-f002" ref-type="fig">Figure 2</xref>. In addition, a summary of the in vitro studies on SAL, alone and its combination with other agents in various cancer models, is given in <xref rid="medsci-13-00047-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec7-medsci-13-00047"><title>7. DCA and SAL as a Combination Therapy</title><p>Skeberdyt&#x00117; and colleagues were among the first to recognize that DCA had synergistic potential with SAL. In a study, the group tested the efficacy of DCA and SAL combination therapy on human colorectal cancer-derived cell lines DLD-1 and HCT116 [<xref rid="B108-medsci-13-00047" ref-type="bibr">108</xref>]. DCA and SAL were found to synergistically inhibit the viability of the DLD-1 and HCT116 cell lines in 2D and 3D cultures. In both tests, DCA and SAL were reported to have a dramatically increased cytotoxic effect in combination, in contrast to their use as monotherapies. This was especially prevalent in the DLD-1 3D cultures, which had a greater prevalence of CSCs, supporting the previously discussed mechanisms observed for SAL [<xref rid="B108-medsci-13-00047" ref-type="bibr">108</xref>]. In summary, the relationship between these two compounds seems to be the following: DCA sensitizes cancer cells via modulating the Warburg effect, making them more vulnerable to apoptotic agents, such as SAL [<xref rid="B108-medsci-13-00047" ref-type="bibr">108</xref>]. This mechanism is viable because both DCA and SAL synergistically target mitochondrial function. Overall, DCA has been shown repeatedly to inhibit PDK in anaerobic glycolysis, while SAL redirects ion flux through the cytoplasm and mitochondrial membrane. Moreover, DCA has been shown, via a calcein fluorescence assay, to induce a greater cellular retention of SAL, which is another indicator of its ability to sensitize cancer cells [<xref rid="B108-medsci-13-00047" ref-type="bibr">108</xref>]. One of the most concerning aspects of SAL is its frequently observed induction of autophagy in both combination and monotherapies. In that same assay, there was no observed calcein removal and the calcein fluorescence delay was shown to be mediated by DCA. This detail shows that DCA/SAL combination therapy has a lower susceptibility to resistance [<xref rid="B108-medsci-13-00047" ref-type="bibr">108</xref>]. While the 3D cultures were able to imitate some of the complexity inherent in in vivo assays, more research is needed to validate these observations.</p><p>In their next studies on DCA and SAL, Skeberdyt&#x00117; and colleagues observed a similar effect in an LLC1 Lewis lung cancer cell line implanted in C57BL/6 mice [<xref rid="B109-medsci-13-00047" ref-type="bibr">109</xref>]. DCA and SAL were found to significantly suppress tumor growth in vivo in the mice. In this report, there was a greater emphasis on studying the mechanisms of SAL on CSCs and the EMT process. In addition to preventing the local metastasis of LLC1 in C57BL/6 mice, DCA/SAL were shown to reduce the EMT transition and CSC markers in combination therapy. This is significant, because CSCs are not only an important player in metastasis formation, but also significantly contribute to the development of chemotherapeutic resistance and tumor relapse [<xref rid="B109-medsci-13-00047" ref-type="bibr">109</xref>]. A few limitations of this study were that the majority of the generated results were performed with in vitro assays. Despite the promising findings, their applicability to complex systems remains limited [<xref rid="B109-medsci-13-00047" ref-type="bibr">109</xref>]. Further studies should aim to investigate the effects of DCA and SAL combination therapy in vivo to properly elucidate their systemic effects on tumor heterogeneity and metastasis.</p></sec><sec sec-type="conclusions" id="sec8-medsci-13-00047"><title>8. Conclusions and Future Perspectives</title><p>Metastasis and resistance continue to be some of the most important challenges in the treatment of malignancies, including NSCLC, indicating the need for alternative approaches. DCA and SAL have been shown to exert promising anticancer properties as monotherapies, and to also synergize with other therapeutic agents and regulate/inhibit cancer activities, including glucose metabolism, cell viability, and proliferation. Importantly, DCA/SAL combination therapy seems to have a particularly potent effect on the prevention of metastasis. SAL has been repeatedly shown to interrupt EMT and DCA enhances its cytotoxic effect, in addition to being an anti-proliferative agent. In regard to resistance, SAL selectively targets CSCs via mitochondrial dysfunction and DCA resensitizes cancer cells to apoptotic agents through metabolic modulation. This has been shown consistently by the cited research in this review, against multiple cancer types, including NSCLC cells. Autophagy, being one of the most significant potential caveats against recommending the usage of SAL, has been shown to be inhibited by DCA in NSCLC as well as in the colorectal cancer studies. Additionally, in the Lewis lung cancer study, a combination therapy was shown to have a much greater effect on the proliferation of CSCs and EMT markers in vivo.</p><p>While DCA and SAL&#x02019;s synergy has not been exploited in great detail yet, their use as monotherapies has repeatedly been shown to be effective in in vitro and in vivo models of various forms of cancer, including NSCLC, with similar physiologies and accompanying challenges. In conjunction with chemotherapy and targeted molecular approaches, DCA and SAL combination treatment could be effective against resistance and metastasis in multiple tumor types, including NSCLC. In addition to DCA, its derivative, diisopropylamine dichloroacetate (DADA), has also been shown to modulate the tumor microenvironment (TME) of NSCLC via its ability to induce T-cell regeneration by decreasing lactic acid production [<xref rid="B110-medsci-13-00047" ref-type="bibr">110</xref>]. Along similar lines, SAL-loaded liposomes containing tumor-derived nanovesicles have been shown to target the TME via inducing the immunogenic cell death of syngeneic colon cancer and melanoma tumor cells, mediated via enhanced antigen presentation by dendritic cells and macrophage polarization toward the M1 phenotype [<xref rid="B111-medsci-13-00047" ref-type="bibr">111</xref>]. These studies have indicated that the use of DADA and SAL could be explored to enhance the efficacy of immunotherapeutic approaches for cancer treatment.</p><p>Notably, while the experimental results have indicated some anti-resistance efficacy of DCA and SAL, there are still more anti-resistance mechanisms to be elucidated. To that end, the utilization of the CRISPR/Cas9 system, an RNA-based adaptive immune system found in bacteria and archaea, has shown the potential to target the genes involved in cancer resistance [<xref rid="B112-medsci-13-00047" ref-type="bibr">112</xref>]. The testing of agents like DCA and SAL through CRISPR/Cas9- isolated RNA could help researchers understand what resistance-contributing genes this synergy affects. Similarly, single-cell RNA sequencing could be used to understand how this synergy alters transcription factors and other mediators within metabolic and pro-apoptotic signaling cascades [<xref rid="B113-medsci-13-00047" ref-type="bibr">113</xref>,<xref rid="B114-medsci-13-00047" ref-type="bibr">114</xref>].</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, S.H., A.T. and R.P.S.; software, A.T.; writing&#x02014;first draft preparation, S.H., A.T. and R.P.S.; writing&#x02014;review and editing, S.H., A.T. and R.P.S.; supervision, R.P.S.; funding acquisition, R.P.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data are included in this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC </td><td align="left" valign="middle" rowspan="1" colspan="1">Non-small-cell lung cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCA </td><td align="left" valign="middle" rowspan="1" colspan="1">Dichloroacetate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SAL </td><td align="left" valign="middle" rowspan="1" colspan="1">Salinomycin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SCLC </td><td align="left" valign="middle" rowspan="1" colspan="1">Small-cell lung carcinoma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AMPK</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenosine monophosphate-activated protein kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGFR </td><td align="left" valign="middle" rowspan="1" colspan="1">Epidermal growth factor receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TKIs </td><td align="left" valign="middle" rowspan="1" colspan="1">Tyrosine kinase inhibitors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDK </td><td align="left" valign="middle" rowspan="1" colspan="1">Pyruvate dehydrogenase kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Cancer stem cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDC </td><td align="left" valign="middle" rowspan="1" colspan="1">Pyruvate dehydrogenase complex</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCA </td><td align="left" valign="middle" rowspan="1" colspan="1">Tricarboxylic acid cycle</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OXPHOS </td><td align="left" valign="middle" rowspan="1" colspan="1">Oxidative phosphorylation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDHE1&#x003b1; </td><td align="left" valign="middle" rowspan="1" colspan="1">Pyruvate dehydrogenase E1 subunit 1 alpha</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIF1&#x003b1; </td><td align="left" valign="middle" rowspan="1" colspan="1">Hypoxia-inducible factor 1 alpha</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MTCs </td><td align="left" valign="middle" rowspan="1" colspan="1">Mono-carboxylic transporter proteins</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS </td><td align="left" valign="middle" rowspan="1" colspan="1">Reactive oxygen species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HUVEC </td><td align="left" valign="middle" rowspan="1" colspan="1">Human umbilical vein endothelial cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EMT </td><td align="left" valign="middle" rowspan="1" colspan="1">Epithelial&#x02013;mesenchymal transition</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGFs </td><td align="left" valign="middle" rowspan="1" colspan="1">Transforming growth factors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF&#x003b2; </td><td align="left" valign="middle" rowspan="1" colspan="1">Transforming growth factor &#x003b2;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cytc </td><td align="left" valign="middle" rowspan="1" colspan="1">Cytochrome c</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ER</td><td align="left" valign="middle" rowspan="1" colspan="1">Endoplasmic reticulum</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HNC </td><td align="left" valign="middle" rowspan="1" colspan="1">Head and neck cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ERK1/2</td><td align="left" valign="middle" rowspan="1" colspan="1">Extracellular signal-regulated kinase &#x000bd;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HGG </td><td align="left" valign="middle" rowspan="1" colspan="1">High-grade glioma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mTOR</td><td align="left" valign="middle" rowspan="1" colspan="1">Mammalian targets of rapamycin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LC3</td><td align="left" valign="middle" rowspan="1" colspan="1">Microtubule-associated protein 1 light chain 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LC3B</td><td align="left" valign="middle" rowspan="1" colspan="1">LC3 isoform B</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p62</td><td align="left" valign="middle" rowspan="1" colspan="1">Sequestosome-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Wnt </td><td align="left" valign="middle" rowspan="1" colspan="1">Wingless-related integration site pathway</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AKT-CA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ak strain transforming protein kinase B (Ca<sup>2+</sup>)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TS</td><td align="left" valign="middle" rowspan="1" colspan="1">Thymidylate synthase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SIRT1</td><td align="left" valign="middle" rowspan="1" colspan="1">Sirtuin gene 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NAG-1</td><td align="left" valign="middle" rowspan="1" colspan="1">NSAID-activated gene</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATF4</td><td align="left" valign="middle" rowspan="1" colspan="1">Activating transcription factor 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DDIT3</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA damage-inducible transcript 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHOP </td><td align="left" valign="middle" rowspan="1" colspan="1">C/EBP homologous protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TRIB3</td><td align="left" valign="middle" rowspan="1" colspan="1">Tribbles pseudokinase 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AKT1</td><td align="left" valign="middle" rowspan="1" colspan="1">AKT serine/threonine kinase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DADA</td><td align="left" valign="middle" rowspan="1" colspan="1">Diisopropylamine dichloroacetate </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TME</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor microenvironment </td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-medsci-13-00047"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siegel</surname><given-names>R.L.</given-names></name>
<name><surname>Giaquinto</surname><given-names>A.N.</given-names></name>
<name><surname>Jemal</surname><given-names>A.</given-names></name>
</person-group><article-title>Cancer Statistics, 2024</article-title><source>CA A Cancer J. Clin.</source><year>2024</year><volume>74</volume><fpage>12</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21820</pub-id><pub-id pub-id-type="pmid">38230766</pub-id>
</element-citation></ref><ref id="B2-medsci-13-00047"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanahan</surname><given-names>D.</given-names></name>
</person-group><article-title>Hallmarks of cancer: New dimensions</article-title><source>Cancer Discov.</source><year>2022</year><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id><pub-id pub-id-type="pmid">35022204</pub-id>
</element-citation></ref><ref id="B3-medsci-13-00047"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schabath</surname><given-names>M.B.</given-names></name>
<name><surname>Cote</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Cancer Progress and Priorities: Lung Cancer</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2019</year><volume>28</volume><fpage>1563</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-19-0221</pub-id><pub-id pub-id-type="pmid">31575553</pub-id>
</element-citation></ref><ref id="B4-medsci-13-00047"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bade</surname><given-names>B.C.</given-names></name>
<name><surname>Cruz</surname><given-names>C.S.D.</given-names></name>
</person-group><article-title>Lung Cancer 2020: Epidemiology, Etiology, and Prevention</article-title><source>Clin. Chest Med.</source><year>2020</year><volume>41</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.ccm.2019.10.001</pub-id><pub-id pub-id-type="pmid">32008623</pub-id>
</element-citation></ref><ref id="B5-medsci-13-00047"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>R.A.</given-names></name>
<name><surname>Glynn</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Epidemiology of lung cancer</article-title><source>Radiol. Clin. N. Am.</source><year>2000</year><volume>38</volume><fpage>453</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/S0033-8389(05)70176-7</pub-id><pub-id pub-id-type="pmid">10855253</pub-id>
</element-citation></ref><ref id="B6-medsci-13-00047"><label>6.</label><element-citation publication-type="webpage"><article-title>Lung Cancer Statistics|How Common is Lung Cancer? (n.d.). American Cancer Society</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html" ext-link-type="uri">https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-01">(accessed on 1 April 2025)</date-in-citation></element-citation></ref><ref id="B7-medsci-13-00047"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Molina</surname><given-names>J.R.</given-names></name>
<name><surname>Yang</surname><given-names>P.</given-names></name>
</person-group><article-title>Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship</article-title><source>Mayo Clin. Proc.</source><year>2008</year><volume>83</volume><fpage>584</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/S0025-6196(11)60735-0</pub-id><pub-id pub-id-type="pmid">18452692</pub-id>
</element-citation></ref><ref id="B8-medsci-13-00047"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walker</surname><given-names>S.</given-names></name>
</person-group><article-title>Updates in non-small cell lung cancer</article-title><source>Clin. J. Oncol. Nurs.</source><year>2008</year><volume>12</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1188/08.CJON.587-596</pub-id><pub-id pub-id-type="pmid">18676326</pub-id>
</element-citation></ref><ref id="B9-medsci-13-00047"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.W.</given-names></name>
<name><surname>Lee</surname><given-names>C.H.</given-names></name>
<name><surname>Park</surname><given-names>Y.S.</given-names></name>
</person-group><article-title>Location of stage I-III non-small cell lung cancer and survival rate: Systematic review and meta-analysis</article-title><source>Thorac. Cancer</source><year>2018</year><volume>9</volume><fpage>1614</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.1111/1759-7714.12869</pub-id><pub-id pub-id-type="pmid">30259691</pub-id>
</element-citation></ref><ref id="B10-medsci-13-00047"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>B.</given-names></name>
<name><surname>He</surname><given-names>S.</given-names></name>
</person-group><article-title>Advances and challenges in the treatment of lung cancer</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>169</volume><elocation-id>115891</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115891</pub-id><pub-id pub-id-type="pmid">37979378</pub-id>
</element-citation></ref><ref id="B11-medsci-13-00047"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Lin</surname><given-names>Z.</given-names></name>
</person-group><article-title>Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>15056</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232315056</pub-id><pub-id pub-id-type="pmid">36499382</pub-id>
</element-citation></ref><ref id="B12-medsci-13-00047"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>M.</given-names></name>
<name><surname>Sarkar</surname><given-names>A.</given-names></name>
</person-group><article-title>Current therapeutic strategies and challenges in nsclc treatment: A comprehensive review</article-title><source>Exp. Oncol.</source><year>2022</year><volume>44</volume><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.32471/exp-oncology.2312-8852.vol-44-no-1.17411</pub-id><pub-id pub-id-type="pmid">35548961</pub-id>
</element-citation></ref><ref id="B13-medsci-13-00047"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>R.F.</given-names></name>
<name><surname>Zhu</surname><given-names>M.L.</given-names></name>
<name><surname>Liu</surname><given-names>M.M.</given-names></name>
<name><surname>Xu</surname><given-names>Y.T.</given-names></name>
<name><surname>Yuan</surname><given-names>L.L.</given-names></name>
<name><surname>Bian</surname><given-names>J.</given-names></name>
<name><surname>Xia</surname><given-names>Y.Z.</given-names></name>
<name><surname>Kong</surname><given-names>L.Y.</given-names></name>
</person-group><article-title>EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research</article-title><source>Pharmacol. Res.</source><year>2021</year><volume>167</volume><fpage>105583</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105583</pub-id><pub-id pub-id-type="pmid">33775864</pub-id>
</element-citation></ref><ref id="B14-medsci-13-00047"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castellanos</surname><given-names>E.</given-names></name>
<name><surname>Feld</surname><given-names>E.</given-names></name>
<name><surname>Horn</surname><given-names>L.</given-names></name>
</person-group><article-title>Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer</article-title><source>J. Thorac. Oncol.</source><year>2017</year><volume>12</volume><fpage>612</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2016.12.014</pub-id><pub-id pub-id-type="pmid">28017789</pub-id>
</element-citation></ref><ref id="B15-medsci-13-00047"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoneda</surname><given-names>K.</given-names></name>
<name><surname>Imanishi</surname><given-names>N.</given-names></name>
<name><surname>Ichiki</surname><given-names>Y.</given-names></name>
<name><surname>Tanaka</surname><given-names>F.</given-names></name>
</person-group><article-title>Treatment of Non-small Cell Lung Cancer with EGFR-mutations</article-title><source>J. UOEH</source><year>2019</year><volume>41</volume><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.7888/juoeh.41.153</pub-id><pub-id pub-id-type="pmid">31292359</pub-id>
</element-citation></ref><ref id="B16-medsci-13-00047"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>A.</given-names></name>
<name><surname>Rajan</surname><given-names>A.</given-names></name>
<name><surname>Giaccone</surname><given-names>G.</given-names></name>
</person-group><article-title>Tyrosine kinase inhibitors in lung cancer</article-title><source>Hematol. Oncol. Clin. N. Am.</source><year>2012</year><volume>26</volume><fpage>589</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2012.02.001</pub-id></element-citation></ref><ref id="B17-medsci-13-00047"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiao</surname><given-names>Q.</given-names></name>
<name><surname>Bi</surname><given-names>L.</given-names></name>
<name><surname>Ren</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>Y.S.</given-names></name>
</person-group><article-title>Advances in studies of tyrosine kinase inhibitors and their acquired resistance</article-title><source>Mol. Cancer</source><year>2018</year><volume>17</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s12943-018-0801-5</pub-id><pub-id pub-id-type="pmid">29455664</pub-id>
</element-citation></ref><ref id="B18-medsci-13-00047"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tibes</surname><given-names>R.</given-names></name>
<name><surname>Trent</surname><given-names>J.</given-names></name>
<name><surname>Kurzrock</surname><given-names>R.</given-names></name>
</person-group><article-title>Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2005</year><volume>45</volume><fpage>357</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.100124</pub-id><pub-id pub-id-type="pmid">15822181</pub-id>
</element-citation></ref><ref id="B19-medsci-13-00047"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>B.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
<name><surname>Youn</surname><given-names>H.</given-names></name>
<name><surname>Youn</surname><given-names>B.</given-names></name>
</person-group><article-title>The Warburg effect on radioresistance: Survival beyond growth</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><year>2023</year><volume>1878</volume><elocation-id>188988</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbcan.2023.188988</pub-id><pub-id pub-id-type="pmid">37726064</pub-id>
</element-citation></ref><ref id="B20-medsci-13-00047"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaupel</surname><given-names>P.</given-names></name>
<name><surname>Schmidberger</surname><given-names>H.</given-names></name>
<name><surname>Mayer</surname><given-names>A.</given-names></name>
</person-group><article-title>The Warburg effect: Essential part of metabolic reprogramming and central contributor to cancer progression</article-title><source>Int. J. Radiat. Biol.</source><year>2019</year><volume>95</volume><fpage>912</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1080/09553002.2019.1589653</pub-id><pub-id pub-id-type="pmid">30822194</pub-id>
</element-citation></ref><ref id="B21-medsci-13-00047"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>L.</given-names></name>
<name><surname>Supuran</surname><given-names>C.T.</given-names></name>
<name><surname>Alfarouk</surname><given-names>K.O.</given-names></name>
</person-group><article-title>The Warburg Effect and the Hallmarks of Cancer</article-title><source>Anticancer. Agents Med. Chem.</source><year>2017</year><volume>17</volume><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.2174/1871520616666161031143301</pub-id><pub-id pub-id-type="pmid">27804847</pub-id>
</element-citation></ref><ref id="B22-medsci-13-00047"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Icard</surname><given-names>P.</given-names></name>
<name><surname>Shulman</surname><given-names>S.</given-names></name>
<name><surname>Farhat</surname><given-names>D.</given-names></name>
<name><surname>Steyaert</surname><given-names>J.M.</given-names></name>
<name><surname>Alifano</surname><given-names>M.</given-names></name>
<name><surname>Lincet</surname><given-names>H.</given-names></name>
</person-group><article-title>How the Warburg effect supports aggressiveness and drug resistance of cancer cells?</article-title><source>Drug Resist. Updat.</source><year>2018</year><volume>38</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2018.03.001</pub-id><pub-id pub-id-type="pmid">29857814</pub-id>
</element-citation></ref><ref id="B23-medsci-13-00047"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liberti</surname><given-names>M.V.</given-names></name>
<name><surname>Locasale</surname><given-names>J.W.</given-names></name>
</person-group><article-title>The Warburg Effect: How Does it Benefit Cancer Cells?</article-title><source>Trends Biochem. Sci.</source><year>2016</year><volume>41</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2015.12.001</pub-id><pub-id pub-id-type="pmid">26778478</pub-id>
</element-citation></ref><ref id="B24-medsci-13-00047"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kankotia</surname><given-names>S.</given-names></name>
<name><surname>Stacpoole</surname><given-names>P.W.</given-names></name>
</person-group><article-title>Dichloroacetate and cancer: New home for an orphan drug?</article-title><source>Biochem. Biophys. Acta</source><year>2014</year><volume>1846</volume><fpage>617</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2014.08.005</pub-id><pub-id pub-id-type="pmid">25157892</pub-id>
</element-citation></ref><ref id="B25-medsci-13-00047"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koltai</surname><given-names>T.</given-names></name>
<name><surname>Fliegel</surname><given-names>L.</given-names></name>
</person-group><article-title>Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><elocation-id>744</elocation-id><pub-id pub-id-type="doi">10.3390/ph17060744</pub-id><pub-id pub-id-type="pmid">38931411</pub-id>
</element-citation></ref><ref id="B26-medsci-13-00047"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naujokat</surname><given-names>C.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Opelz</surname><given-names>G.</given-names></name>
</person-group><article-title>Salinomycin in cancer: A new mission for an old agent</article-title><source>Mol. Med. Rep.</source><year>2010</year><volume>3</volume><fpage>555</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.3892/mmr_00000296</pub-id><pub-id pub-id-type="pmid">21472278</pub-id>
</element-citation></ref><ref id="B27-medsci-13-00047"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naujokat</surname><given-names>C.</given-names></name>
<name><surname>Steinhart</surname><given-names>R.</given-names></name>
</person-group><article-title>Salinomycin as a drug for targeting human cancer stem cells</article-title><source>J. Biomed. Biotechnol.</source><year>2012</year><volume>2012</volume><elocation-id>950658</elocation-id><pub-id pub-id-type="doi">10.1155/2012/950658</pub-id><pub-id pub-id-type="pmid">23251084</pub-id>
</element-citation></ref><ref id="B28-medsci-13-00047"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Wong</surname><given-names>E.T.</given-names></name>
<name><surname>Fonkem</surname><given-names>E.</given-names></name>
<name><surname>Hsieh</surname><given-names>T.C.</given-names></name>
<name><surname>Wu</surname><given-names>J.M.</given-names></name>
<name><surname>Wu</surname><given-names>E.</given-names></name>
</person-group><article-title>Salinomycin: A novel anti-cancer agent with known anti-coccidial activities</article-title><source>Curr. Med. Chem.</source><year>2013</year><volume>20</volume><fpage>4095</fpage><lpage>4101</lpage><pub-id pub-id-type="doi">10.2174/15672050113109990199</pub-id><pub-id pub-id-type="pmid">23931281</pub-id>
</element-citation></ref><ref id="B29-medsci-13-00047"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Cui</surname><given-names>C.</given-names></name>
<name><surname>Cai</surname><given-names>F.</given-names></name>
</person-group><article-title>Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>654428</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.654428</pub-id><pub-id pub-id-type="pmid">34381705</pub-id>
</element-citation></ref><ref id="B30-medsci-13-00047"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huczynski</surname><given-names>A.</given-names></name>
</person-group><article-title>Salinomycin: A new cancer drug candidate</article-title><source>Chem. Biol. Drug Des.</source><year>2012</year><volume>79</volume><fpage>235</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1111/j.1747-0285.2011.01287.x</pub-id><pub-id pub-id-type="pmid">22145602</pub-id>
</element-citation></ref><ref id="B31-medsci-13-00047"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stacpoole</surname><given-names>P.W.</given-names></name>
<name><surname>Greene</surname><given-names>Y.J.</given-names></name>
</person-group><article-title>Dichloroacetate</article-title><source>Diabetes Care</source><year>1992</year><volume>15</volume><fpage>785</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.2337/diacare.15.6.785</pub-id><pub-id pub-id-type="pmid">1600837</pub-id>
</element-citation></ref><ref id="B32-medsci-13-00047"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stacpoole</surname><given-names>P.W.</given-names></name>
</person-group><article-title>The pharmacology of dichloroacetate</article-title><source>Metabolism</source><year>1989</year><volume>38</volume><fpage>1124</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1016/0026-0495(89)90051-6</pub-id><pub-id pub-id-type="pmid">2554095</pub-id>
</element-citation></ref><ref id="B33-medsci-13-00047"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tataranni</surname><given-names>T.</given-names></name>
<name><surname>Piccoli</surname><given-names>C.</given-names></name>
</person-group><article-title>Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications</article-title><source>Oxid. Med. Cell Longev.</source><year>2019</year><volume>2019</volume><fpage>8201079</fpage><pub-id pub-id-type="doi">10.1155/2019/8201079</pub-id><pub-id pub-id-type="pmid">31827705</pub-id>
</element-citation></ref><ref id="B34-medsci-13-00047"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romero</surname><given-names>Y.</given-names></name>
<name><surname>Castillejos-L&#x000f3;pez</surname><given-names>M.</given-names></name>
<name><surname>Romero-Garc&#x000ed;a</surname><given-names>S.</given-names></name>
<name><surname>Aguayo</surname><given-names>A.S.</given-names></name>
<name><surname>Herrera</surname><given-names>I.</given-names></name>
<name><surname>Garcia-Martin</surname><given-names>M.O.</given-names></name>
<name><surname>Torres-Esp&#x000ed;ndola</surname><given-names>L.M.</given-names></name>
<name><surname>Negrete-Garc&#x000ed;a</surname><given-names>M.C.</given-names></name>
<name><surname>Olvera</surname><given-names>A.C.</given-names></name>
<name><surname>Huerta-Cruz</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>Antitumor Therapy under Hypoxic Microenvironment by the Combination of 2-Methoxyestradiol and Sodium Dichloroacetate on Human Non-Small-Cell Lung Cancer</article-title><source>Oxid. Med. Cell Longev.</source><year>2020</year><volume>2020</volume><fpage>3176375</fpage><pub-id pub-id-type="doi">10.1155/2020/3176375</pub-id><pub-id pub-id-type="pmid">33149807</pub-id>
</element-citation></ref><ref id="B35-medsci-13-00047"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michelakis</surname><given-names>E.D.</given-names></name>
<name><surname>Webster</surname><given-names>L.</given-names></name>
<name><surname>Mackey</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer</article-title><source>Br. J. Cancer</source><year>2008</year><volume>99</volume><fpage>989</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604554</pub-id><pub-id pub-id-type="pmid">18766181</pub-id>
</element-citation></ref><ref id="B36-medsci-13-00047"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sutendra</surname><given-names>G.</given-names></name>
<name><surname>Dromparis</surname><given-names>P.</given-names></name>
<name><surname>Kinnaird</surname><given-names>A.</given-names></name>
<name><surname>Stenson</surname><given-names>T.H.</given-names></name>
<name><surname>Haromy</surname><given-names>A.</given-names></name>
<name><surname>Parker</surname><given-names>J.M.</given-names></name>
<name><surname>McMurtry</surname><given-names>M.S.</given-names></name>
<name><surname>Michelakis</surname><given-names>E.D.</given-names></name>
</person-group><article-title>Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>1638</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.198</pub-id><pub-id pub-id-type="pmid">22614004</pub-id>
</element-citation></ref><ref id="B37-medsci-13-00047"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dyrstad</surname><given-names>S.E.</given-names></name>
<name><surname>Lotsberg</surname><given-names>M.L.</given-names></name>
<name><surname>Tan</surname><given-names>T.Z.</given-names></name>
<name><surname>Pettersen</surname><given-names>I.K.N.</given-names></name>
<name><surname>Hjellbrekke</surname><given-names>S.</given-names></name>
<name><surname>Tusubira</surname><given-names>D.</given-names></name>
<name><surname>Engelsen</surname><given-names>A.S.T.</given-names></name>
<name><surname>Daubon</surname><given-names>T.</given-names></name>
<name><surname>Mourier</surname><given-names>A.</given-names></name>
<name><surname>Thiery</surname><given-names>J.P.</given-names></name>
<etal/>
</person-group><article-title>Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>941</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13050941</pub-id><pub-id pub-id-type="pmid">33668151</pub-id>
</element-citation></ref><ref id="B38-medsci-13-00047"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x00160;korja Mili&#x00107;</surname><given-names>N.</given-names></name>
<name><surname>Dolinar</surname><given-names>K.</given-names></name>
<name><surname>Mi&#x00161;</surname><given-names>K.</given-names></name>
<name><surname>Matkovi&#x0010d;</surname><given-names>U.</given-names></name>
<name><surname>Bizjak</surname><given-names>M.</given-names></name>
<name><surname>Pavlin</surname><given-names>M.</given-names></name>
<name><surname>Podbregar</surname><given-names>M.</given-names></name>
<name><surname>Pirkmajer</surname><given-names>S.</given-names></name>
</person-group><article-title>Suppression of Pyruvate Dehydrogenase Kinase by Dichloroacetate in Cancer and Skeletal Muscle Cells Is Isoform Specific and Partially Independent of HIF-1&#x003b1;</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>8610</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22168610</pub-id><pub-id pub-id-type="pmid">34445316</pub-id>
</element-citation></ref><ref id="B39-medsci-13-00047"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdel-Wahab</surname><given-names>A.F.</given-names></name>
<name><surname>Mahmoud</surname><given-names>W.</given-names></name>
<name><surname>Al-Harizy</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Targeting glucose metabolism to suppress cancer progression: Prospective of anti-glycolytic cancer therapy</article-title><source>Pharmacol. Res.</source><year>2019</year><volume>150</volume><fpage>104511</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104511</pub-id><pub-id pub-id-type="pmid">31678210</pub-id>
</element-citation></ref><ref id="B40-medsci-13-00047"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>R.C.</given-names></name>
<name><surname>Fadia</surname><given-names>M.</given-names></name>
<name><surname>Dahlstrom</surname><given-names>J.E.</given-names></name>
<name><surname>Parish</surname><given-names>C.R.</given-names></name>
<name><surname>Board</surname><given-names>P.G.</given-names></name>
<name><surname>Blackburn</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo</article-title><source>Breast Cancer Res. Treat.</source><year>2010</year><volume>120</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1007/s10549-009-0435-9</pub-id><pub-id pub-id-type="pmid">19543830</pub-id>
</element-citation></ref><ref id="B41-medsci-13-00047"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shavit</surname><given-names>R.</given-names></name>
<name><surname>Ilouze</surname><given-names>M.</given-names></name>
<name><surname>Feinberg</surname><given-names>T.</given-names></name>
<name><surname>Lawrence</surname><given-names>Y.R.</given-names></name>
<name><surname>Tzur</surname><given-names>Y.</given-names></name>
<name><surname>Peled</surname><given-names>N.</given-names></name>
</person-group><article-title>Mitochondrial induction as a potential radio-sensitizer in lung cancer cells&#x02014;A short report</article-title><source>Cell. Oncol.</source><year>2015</year><volume>38</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1007/s13402-014-0212-6</pub-id></element-citation></ref><ref id="B42-medsci-13-00047"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>K.T.</given-names></name>
<name><surname>Chin-Sinex</surname><given-names>H.</given-names></name>
<name><surname>DeLuca</surname><given-names>T.</given-names></name>
<name><surname>Pomerening</surname><given-names>J.R.</given-names></name>
<name><surname>Sherer</surname><given-names>J.</given-names></name>
<name><surname>Watkins</surname><given-names>J.B.</given-names><suffix>3rd</suffix></name>
<name><surname>Foley</surname><given-names>J.</given-names></name>
<name><surname>Jesseph</surname><given-names>J.M.</given-names></name>
<name><surname>Mendonca</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Dichloroacetate alters Warburg metabolism, inhibits cell growth, and increases the X-ray sensitivity of human A549 and H1299 NSC lung cancer cells</article-title><source>Free Radic. Biol. Med.</source><year>2015</year><volume>89</volume><fpage>263</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.08.006</pub-id><pub-id pub-id-type="pmid">26393423</pub-id>
</element-citation></ref><ref id="B43-medsci-13-00047"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tran</surname><given-names>Q.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>S.H.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
</person-group><article-title>Targeting Cancer Metabolism&#x02014;Revisiting the Warburg Effects</article-title><source>Toxicol. Res.</source><year>2016</year><volume>32</volume><fpage>177</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.5487/TR.2016.32.3.177</pub-id><pub-id pub-id-type="pmid">27437085</pub-id>
</element-citation></ref><ref id="B44-medsci-13-00047"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.J.</given-names></name>
<name><surname>Lei</surname><given-names>Y.H.</given-names></name>
<name><surname>Yao</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>C.R.</given-names></name>
<name><surname>Hu</surname><given-names>N.</given-names></name>
<name><surname>Ye</surname><given-names>W.C.</given-names></name>
<name><surname>Zhang</surname><given-names>D.M.</given-names></name>
<name><surname>Chen</surname><given-names>Z.S.</given-names></name>
</person-group><article-title>Autophagy and multidrug resistance in cancer</article-title><source>Chin. J. Cancer</source><year>2017</year><volume>36</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1186/s40880-017-0219-2</pub-id><pub-id pub-id-type="pmid">28646911</pub-id>
</element-citation></ref><ref id="B45-medsci-13-00047"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vempati</surname><given-names>R.K.</given-names></name>
<name><surname>Malla</surname><given-names>R.R.</given-names></name>
</person-group><article-title>Autophagy-Induced Drug Resistance in Liver Cancer</article-title><source>Crit. Rev. Oncog.</source><year>2020</year><volume>25</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1615/CritRevOncog.2020034969</pub-id><pub-id pub-id-type="pmid">32865908</pub-id>
</element-citation></ref><ref id="B46-medsci-13-00047"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levine</surname><given-names>B.</given-names></name>
<name><surname>Kroemer</surname><given-names>G.</given-names></name>
</person-group><article-title>Biological Functions of Autophagy Genes: A Disease Perspective</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>11</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.09.048</pub-id><pub-id pub-id-type="pmid">30633901</pub-id>
</element-citation></ref><ref id="B47-medsci-13-00047"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>G.</given-names></name>
<name><surname>Hill</surname><given-names>D.K.</given-names></name>
<name><surname>Andrejeva</surname><given-names>G.</given-names></name>
<name><surname>Boult</surname><given-names>J.K.</given-names></name>
<name><surname>Troy</surname><given-names>H.</given-names></name>
<name><surname>Fong</surname><given-names>A.C.</given-names></name>
<name><surname>Orton</surname><given-names>M.R.</given-names></name>
<name><surname>Panek</surname><given-names>R.</given-names></name>
<name><surname>Parkes</surname><given-names>H.G.</given-names></name>
<name><surname>Jafar</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Dichloroacetate induces autophagy in colorectal cancer cells and tumours</article-title><source>Br. J. Cancer</source><year>2014</year><volume>111</volume><fpage>375</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/bjc.2014.281</pub-id><pub-id pub-id-type="pmid">24892448</pub-id>
</element-citation></ref><ref id="B48-medsci-13-00047"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>D.</given-names></name>
<name><surname>Hou</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>Q.X.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Deng</surname><given-names>X.F.</given-names></name>
<name><surname>Yu</surname><given-names>Z.B.</given-names></name>
<name><surname>Dai</surname><given-names>J.G.</given-names></name>
<name><surname>Zheng</surname><given-names>H.</given-names></name>
</person-group><article-title>Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer</article-title><source>Cancer Manag. Res.</source><year>2018</year><volume>10</volume><fpage>1231</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S156530</pub-id><pub-id pub-id-type="pmid">29844702</pub-id>
</element-citation></ref><ref id="B49-medsci-13-00047"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stacpoole</surname><given-names>P.W.</given-names></name>
</person-group><article-title>The dichloroacetate dilemma: Environmental hazard versus therapeutic goldmine--both or neither?</article-title><source>Environ. Health Perspect.</source><year>2011</year><volume>119</volume><fpage>155</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1289/ehp.1002554</pub-id><pub-id pub-id-type="pmid">20920954</pub-id>
</element-citation></ref><ref id="B50-medsci-13-00047"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stacpoole</surname><given-names>P.W.</given-names></name>
<name><surname>Martyniuk</surname><given-names>C.J.</given-names></name>
<name><surname>James</surname><given-names>M.O.</given-names></name>
<name><surname>Calcutt</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Dichloroacetate-induced peripheral neuropathy</article-title><source>Int. Rev. Neurobiol.</source><year>2019</year><volume>145</volume><fpage>211</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/bs.irn.2019.05.003</pub-id><pub-id pub-id-type="pmid">31208525</pub-id>
</element-citation></ref><ref id="B51-medsci-13-00047"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niimi</surname><given-names>N.</given-names></name>
<name><surname>Takaku</surname><given-names>S.</given-names></name>
<name><surname>Yako</surname><given-names>H.</given-names></name>
<name><surname>Sango</surname><given-names>K.</given-names></name>
</person-group><article-title>Drug-Induced Demyelinating Neuropathies</article-title><source>Adv. Exp. Med. Biol.</source><year>2019</year><volume>1190</volume><fpage>357</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1007/978-981-32-9636-7_23</pub-id><pub-id pub-id-type="pmid">31760656</pub-id>
</element-citation></ref><ref id="B52-medsci-13-00047"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>A.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
</person-group><article-title>Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>52642</fpage><lpage>52650</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16991</pub-id><pub-id pub-id-type="pmid">28881758</pub-id>
</element-citation></ref><ref id="B53-medsci-13-00047"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>B.S.</given-names></name>
<name><surname>Yu</surname><given-names>D.H.</given-names></name>
<name><surname>Lu</surname><given-names>Q.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Qi</surname><given-names>H.</given-names></name>
<name><surname>Fang</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>H.Z.</given-names></name>
</person-group><article-title>Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells</article-title><source>Int. J. Oncol.</source><year>2011</year><volume>38</volume><fpage>409</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.3892/ijo.2010.851</pub-id><pub-id pub-id-type="pmid">21132264</pub-id>
</element-citation></ref><ref id="B54-medsci-13-00047"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garon</surname><given-names>E.B.</given-names></name>
<name><surname>Christofk</surname><given-names>H.R.</given-names></name>
<name><surname>Hosmer</surname><given-names>W.</given-names></name>
<name><surname>Britten</surname><given-names>C.D.</given-names></name>
<name><surname>Bahng</surname><given-names>A.</given-names></name>
<name><surname>Crabtree</surname><given-names>M.J.</given-names></name>
<name><surname>Hong</surname><given-names>C.S.</given-names></name>
<name><surname>Kamranpour</surname><given-names>N.</given-names></name>
<name><surname>Pitts</surname><given-names>S.</given-names></name>
<name><surname>Kabbinavar</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2014</year><volume>140</volume><fpage>443</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1007/s00432-014-1583-9</pub-id><pub-id pub-id-type="pmid">24442098</pub-id>
</element-citation></ref><ref id="B55-medsci-13-00047"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Azawi</surname><given-names>A.</given-names></name>
<name><surname>Sulaiman</surname><given-names>S.</given-names></name>
<name><surname>Arafat</surname><given-names>K.</given-names></name>
<name><surname>Yasin</surname><given-names>J.</given-names></name>
<name><surname>Nemmar</surname><given-names>A.</given-names></name>
<name><surname>Attoub</surname><given-names>S.</given-names></name>
</person-group><article-title>Impact of Sodium Dichloroacetate Alone and in Combination Therapies on Lung Tumor Growth and Metastasis</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>12553</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222212553</pub-id><pub-id pub-id-type="pmid">34830434</pub-id>
</element-citation></ref><ref id="B56-medsci-13-00047"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schoenmann</surname><given-names>N.</given-names></name>
<name><surname>Tannenbaum</surname><given-names>N.</given-names></name>
<name><surname>Hodgeman</surname><given-names>R.M.</given-names></name>
<name><surname>Raju</surname><given-names>R.P.</given-names></name>
</person-group><article-title>Regulating mitochondrial metabolism by targeting pyruvate dehydrogenase with dichloroacetate, a metabolic messenger</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><year>2023</year><volume>1869</volume><elocation-id>166769</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2023.166769</pub-id><pub-id pub-id-type="pmid">37263447</pub-id>
</element-citation></ref><ref id="B57-medsci-13-00047"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Jiang</surname><given-names>N.</given-names></name>
<name><surname>Villalobos Solis</surname><given-names>M.I.</given-names></name>
<name><surname>Kara Murdoch</surname><given-names>F.</given-names></name>
<name><surname>Murdoch</surname><given-names>R.W.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Swift</surname><given-names>C.M.</given-names></name>
<name><surname>Hettich</surname><given-names>R.L.</given-names></name>
<name><surname>L&#x000f6;ffler</surname><given-names>F.E.</given-names></name>
</person-group><article-title>Anaerobic Microbial Metabolism of Dichloroacetate</article-title><source>Mbio</source><year>2021</year><volume>12</volume><fpage>e00537-21</fpage><pub-id pub-id-type="doi">10.1128/mBio.00537-21</pub-id><pub-id pub-id-type="pmid">33906923</pub-id>
</element-citation></ref><ref id="B58-medsci-13-00047"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Tam</surname><given-names>K.Y.</given-names></name>
</person-group><article-title>Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines</article-title><source>Eur. J. Pharmacol.</source><year>2016</year><volume>789</volume><fpage>458</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2016.08.004</pub-id><pub-id pub-id-type="pmid">27514773</pub-id>
</element-citation></ref><ref id="B59-medsci-13-00047"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Liao</surname><given-names>C.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Qinwen</surname><given-names>P.</given-names></name>
<name><surname>Jiang</surname><given-names>J.</given-names></name>
</person-group><article-title>Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2017</year><volume>489</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.05.097</pub-id><pub-id pub-id-type="pmid">28528979</pub-id>
</element-citation></ref><ref id="B60-medsci-13-00047"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>M.F.</given-names></name>
<name><surname>Shen</surname><given-names>S.Y.</given-names></name>
<name><surname>Huang</surname><given-names>W.D.</given-names></name>
</person-group><article-title>DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft</article-title><source>Cancer Chemother. Pharmacol.</source><year>2013</year><volume>72</volume><fpage>1031</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1007/s00280-013-2281-z</pub-id><pub-id pub-id-type="pmid">24043136</pub-id>
</element-citation></ref><ref id="B61-medsci-13-00047"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Mey</surname><given-names>S.</given-names></name>
<name><surname>Dufait</surname><given-names>I.</given-names></name>
<name><surname>Jiang</surname><given-names>H.</given-names></name>
<name><surname>Corbet</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Van De Gucht</surname><given-names>M.</given-names></name>
<name><surname>Kerkhove</surname><given-names>L.</given-names></name>
<name><surname>Law</surname><given-names>K.L.</given-names></name>
<name><surname>Vandenplas</surname><given-names>H.</given-names></name>
<name><surname>Gevaert</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>9367</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21249367</pub-id><pub-id pub-id-type="pmid">33316932</pub-id>
</element-citation></ref><ref id="B62-medsci-13-00047"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cook</surname><given-names>K.M.</given-names></name>
<name><surname>Shen</surname><given-names>H.</given-names></name>
<name><surname>McKelvey</surname><given-names>K.J.</given-names></name>
<name><surname>Gee</surname><given-names>H.E.</given-names></name>
<name><surname>Hau</surname><given-names>E.</given-names></name>
</person-group><article-title>Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>7265</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22147265</pub-id><pub-id pub-id-type="pmid">34298883</pub-id>
</element-citation></ref><ref id="B63-medsci-13-00047"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Ni</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zeng</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>J.</given-names></name>
<name><surname>Lyu</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>59458</fpage><lpage>59470</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10694</pub-id><pub-id pub-id-type="pmid">27449090</pub-id>
</element-citation></ref><ref id="B64-medsci-13-00047"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haugrud</surname><given-names>A.B.</given-names></name>
<name><surname>Zhuang</surname><given-names>Y.</given-names></name>
<name><surname>Coppock</surname><given-names>J.D.</given-names></name>
<name><surname>Miskimins</surname><given-names>W.K.</given-names></name>
</person-group><article-title>Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells</article-title><source>Breast Cancer Res. Treat.</source><year>2014</year><volume>147</volume><fpage>539</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1007/s10549-014-3128-y</pub-id><pub-id pub-id-type="pmid">25212175</pub-id>
</element-citation></ref><ref id="B65-medsci-13-00047"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parczyk</surname><given-names>J.</given-names></name>
<name><surname>Ruhnau</surname><given-names>J.</given-names></name>
<name><surname>Pelz</surname><given-names>C.</given-names></name>
<name><surname>Schilling</surname><given-names>M.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Piaskowski</surname><given-names>N.N.</given-names></name>
<name><surname>Eickholt</surname><given-names>B.</given-names></name>
<name><surname>K&#x000fc;hn</surname><given-names>H.</given-names></name>
<name><surname>Danker</surname><given-names>K.</given-names></name>
<name><surname>Klein</surname><given-names>A.</given-names></name>
</person-group><article-title>Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines</article-title><source>BMC Cancer</source><year>2021</year><volume>21</volume><elocation-id>481</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-021-08186-9</pub-id><pub-id pub-id-type="pmid">33931028</pub-id>
</element-citation></ref><ref id="B66-medsci-13-00047"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishiguro</surname><given-names>T.</given-names></name>
<name><surname>Ishiguro</surname><given-names>R.H.</given-names></name>
<name><surname>Ishiguro</surname><given-names>M.</given-names></name>
<name><surname>Toki</surname><given-names>A.</given-names></name>
<name><surname>Terunuma</surname><given-names>H.</given-names></name>
</person-group><article-title>Synergistic Anti-Tumor Effect of Dichloroacetate and Ivermectin</article-title><source>Cureus</source><year>2022</year><volume>14</volume><fpage>e21884</fpage><pub-id pub-id-type="doi">10.7759/cureus.21884</pub-id><pub-id pub-id-type="pmid">35265417</pub-id>
</element-citation></ref><ref id="B67-medsci-13-00047"><label>67.</label><element-citation publication-type="gov"><article-title>Salinomycin. Nih.gov; PubChem</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Salinomycin" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Salinomycin</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-01">(accessed on 1 April 2025)</date-in-citation></element-citation></ref><ref id="B68-medsci-13-00047"><label>68.</label><element-citation publication-type="gov"><article-title>SALINOMYCIN MYCELIA-Salinomycin Powder. <italic toggle="yes">DailyMed</italic> 2020. Nih.gov</article-title><comment>Available online: <ext-link xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76ecb04c-f8c3-4607-9681-1909a3ffb22e" ext-link-type="uri">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76ecb04c-f8c3-4607-9681-1909a3ffb22e</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-01">(accessed on 1 April 2025)</date-in-citation></element-citation></ref><ref id="B69-medsci-13-00047"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aleman</surname><given-names>M.</given-names></name>
<name><surname>Magdesian</surname><given-names>K.G.</given-names></name>
<name><surname>Peterson</surname><given-names>T.S.</given-names></name>
<name><surname>Galey</surname><given-names>F.D.</given-names></name>
</person-group><article-title>Salinomycin toxicosis in horses</article-title><source>J. Am. Vet. Med. Assoc.</source><year>2007</year><volume>230</volume><fpage>1822</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.2460/javma.230.12.1822</pub-id><pub-id pub-id-type="pmid">17571983</pub-id>
</element-citation></ref><ref id="B70-medsci-13-00047"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehlhorn</surname><given-names>H.</given-names></name>
<name><surname>Ganster</surname><given-names>H.J.</given-names></name>
<name><surname>Raether</surname><given-names>W.</given-names></name>
</person-group><article-title>Effect of salinomycin-Na on malaria parasites (<italic toggle="yes">Plasmodium falciparum</italic> and <italic toggle="yes">P. berghei</italic>)</article-title><source>Zentralbl Bakteriol. Mikrobiol. Hyg. A</source><year>1984</year><volume>256</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/S0174-3031(84)80007-4</pub-id><pub-id pub-id-type="pmid">6375210</pub-id>
</element-citation></ref><ref id="B71-medsci-13-00047"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>C.W.</given-names></name>
<name><surname>Peng</surname><given-names>T.T.</given-names></name>
<name><surname>Hsu</surname><given-names>H.Y.</given-names></name>
<name><surname>Lee</surname><given-names>Y.Z.</given-names></name>
<name><surname>Wu</surname><given-names>S.H.</given-names></name>
<name><surname>Lin</surname><given-names>W.H.</given-names></name>
<name><surname>Ke</surname><given-names>Y.Y.</given-names></name>
<name><surname>Hsu</surname><given-names>T.A.</given-names></name>
<name><surname>Yeh</surname><given-names>T.K.</given-names></name>
<name><surname>Huang</surname><given-names>W.Z.</given-names></name>
<etal/>
</person-group><article-title>Repurposing old drugs as antiviral agents for coronaviruses</article-title><source>Biomed. J.</source><year>2020</year><volume>43</volume><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1016/j.bj.2020.05.003</pub-id><pub-id pub-id-type="pmid">32563698</pub-id>
</element-citation></ref><ref id="B72-medsci-13-00047"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>C.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Zhai</surname><given-names>R.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Yang</surname><given-names>Q.</given-names></name>
</person-group><article-title>In Vitro Antiviral Activities of Salinomycin on Porcine Epidemic Diarrhea Virus</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>580</elocation-id><pub-id pub-id-type="doi">10.3390/v13040580</pub-id><pub-id pub-id-type="pmid">33808275</pub-id>
</element-citation></ref><ref id="B73-medsci-13-00047"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huczy&#x00144;ski</surname><given-names>A.</given-names></name>
<name><surname>Janczak</surname><given-names>J.</given-names></name>
<name><surname>Stefa&#x00144;ska</surname><given-names>J.</given-names></name>
<name><surname>Antoszczak</surname><given-names>M.</given-names></name>
<name><surname>Brzezinski</surname><given-names>B.</given-names></name>
</person-group><article-title>Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin</article-title><source>Bioorg Med. Chem. Lett.</source><year>2012</year><volume>22</volume><fpage>4697</fpage><lpage>4702</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.05.081</pub-id><pub-id pub-id-type="pmid">22721714</pub-id>
</element-citation></ref><ref id="B74-medsci-13-00047"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghonaim</surname><given-names>A.H.</given-names></name>
<name><surname>Hopo</surname><given-names>M.G.</given-names></name>
<name><surname>Ismail</surname><given-names>A.K.</given-names></name>
<name><surname>AboElnaga</surname><given-names>T.R.</given-names></name>
<name><surname>Elgawish</surname><given-names>R.A.</given-names></name>
<name><surname>Abdou</surname><given-names>R.H.</given-names></name>
<name><surname>Elhady</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Hepatoprotective and renoprotective effects of silymarin against salinomycin-induced toxicity in adult rabbits</article-title><source>Vet. World</source><year>2022</year><volume>15</volume><fpage>2244</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.14202/vetworld.2022.2244-2252</pub-id><pub-id pub-id-type="pmid">36341068</pub-id>
</element-citation></ref><ref id="B75-medsci-13-00047"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ketola</surname><given-names>K.</given-names></name>
<name><surname>Hilvo</surname><given-names>M.</given-names></name>
<name><surname>Hy&#x000f6;tyl&#x000e4;inen</surname><given-names>T.</given-names></name>
<name><surname>Vuoristo</surname><given-names>A.</given-names></name>
<name><surname>Ruskeep&#x000e4;&#x000e4;</surname><given-names>A.L.</given-names></name>
<name><surname>Ore&#x00161;i&#x0010d;</surname><given-names>M.</given-names></name>
<name><surname>Kallioniemi</surname><given-names>O.</given-names></name>
<name><surname>Iljin</surname><given-names>K.</given-names></name>
</person-group><article-title>Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress</article-title><source>Br. J. Cancer</source><year>2012</year><volume>106</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.530</pub-id><pub-id pub-id-type="pmid">22215106</pub-id>
</element-citation></ref><ref id="B76-medsci-13-00047"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>B.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Lv</surname><given-names>H.</given-names></name>
<name><surname>AlQudsy</surname><given-names>L.H.H.</given-names></name>
<name><surname>Shang</surname><given-names>P.</given-names></name>
</person-group><article-title>Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs</article-title><source>Cancer Lett.</source><year>2020</year><volume>483</volume><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.02.015</pub-id><pub-id pub-id-type="pmid">32067993</pub-id>
</element-citation></ref><ref id="B77-medsci-13-00047"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mai</surname><given-names>T.T.</given-names></name>
<name><surname>Hama&#x000ef;</surname><given-names>A.</given-names></name>
<name><surname>Hienzsch</surname><given-names>A.</given-names></name>
<name><surname>Ca&#x000f1;eque</surname><given-names>T.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>S.</given-names></name>
<name><surname>Wicinski</surname><given-names>J.</given-names></name>
<name><surname>Cabaud</surname><given-names>O.</given-names></name>
<name><surname>Leroy</surname><given-names>C.</given-names></name>
<name><surname>David</surname><given-names>A.</given-names></name>
<name><surname>Acevedo</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Salinomycin kills cancer stem cells by sequestering iron in lysosomes</article-title><source>Nat. Chem.</source><year>2017</year><volume>9</volume><fpage>1025</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1038/nchem.2778</pub-id><pub-id pub-id-type="pmid">28937680</pub-id>
</element-citation></ref><ref id="B78-medsci-13-00047"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antoszczak</surname><given-names>M.</given-names></name>
<name><surname>Huczy&#x00144;ski</surname><given-names>A.</given-names></name>
</person-group><article-title>Anticancer Activity of Polyether Ionophore-Salinomycin</article-title><source>Anticancer Agents Med. Chem.</source><year>2015</year><volume>15</volume><fpage>575</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.2174/1871520615666150101130209</pub-id><pub-id pub-id-type="pmid">25553435</pub-id>
</element-citation></ref><ref id="B79-medsci-13-00047"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nassar</surname><given-names>D.</given-names></name>
<name><surname>Blanpain</surname><given-names>C.</given-names></name>
</person-group><article-title>Cancer Stem Cells: Basic Concepts and Therapeutic Implications</article-title><source>Annu. Rev. Pathol.</source><year>2016</year><volume>11</volume><fpage>47</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-012615-044438</pub-id><pub-id pub-id-type="pmid">27193450</pub-id>
</element-citation></ref><ref id="B80-medsci-13-00047"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Zou</surname><given-names>Q.</given-names></name>
<name><surname>Xu</surname><given-names>P.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Ding</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
</person-group><article-title>Cancer stem cells in colorectal cancer and the association with chemotherapy resistance</article-title><source>Med. Oncol.</source><year>2021</year><volume>38</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1007/s12032-021-01488-9</pub-id><pub-id pub-id-type="pmid">33738588</pub-id>
</element-citation></ref><ref id="B81-medsci-13-00047"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erkisa</surname><given-names>M.</given-names></name>
<name><surname>Karakas</surname><given-names>D.</given-names></name>
<name><surname>Ulukaya</surname><given-names>E.</given-names></name>
</person-group><article-title>Cancer Stem Cells: Root of the Evil</article-title><source>Crit. Rev. Oncog.</source><year>2019</year><volume>24</volume><fpage>69</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1615/CritRevOncog.2019029512</pub-id><pub-id pub-id-type="pmid">31679222</pub-id>
</element-citation></ref><ref id="B82-medsci-13-00047"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makena</surname><given-names>M.R.</given-names></name>
<name><surname>Ranjan</surname><given-names>A.</given-names></name>
<name><surname>Thirumala</surname><given-names>V.</given-names></name>
<name><surname>Reddy</surname><given-names>A.P.</given-names></name>
</person-group><article-title>Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><year>2020</year><volume>1866</volume><elocation-id>165339</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2018.11.015</pub-id><pub-id pub-id-type="pmid">30481586</pub-id>
</element-citation></ref><ref id="B83-medsci-13-00047"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dewangan</surname><given-names>J.</given-names></name>
<name><surname>Srivastava</surname><given-names>S.</given-names></name>
<name><surname>Rath</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Salinomycin: A new paradigm in cancer therapy</article-title><source>Tumour Biol.</source><year>2017</year><volume>39</volume><elocation-id>1010428317695035</elocation-id><pub-id pub-id-type="doi">10.1177/1010428317695035</pub-id><pub-id pub-id-type="pmid">28349817</pub-id>
</element-citation></ref><ref id="B84-medsci-13-00047"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>P.B.</given-names></name>
<name><surname>Onder</surname><given-names>T.T.</given-names></name>
<name><surname>Jiang</surname><given-names>G.</given-names></name>
<name><surname>Tao</surname><given-names>K.</given-names></name>
<name><surname>Kuperwasser</surname><given-names>C.</given-names></name>
<name><surname>Weinberg</surname><given-names>R.A.</given-names></name>
<name><surname>Lander</surname><given-names>E.S.</given-names></name>
</person-group><article-title>Identification of selective inhibitors of cancer stem cells by high-throughput screening</article-title><source>Cell</source><year>2009</year><volume>138</volume><fpage>645</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.06.034</pub-id><pub-id pub-id-type="pmid">19682730</pub-id>
</element-citation></ref><ref id="B85-medsci-13-00047"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qi</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>J.H.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>E.</given-names></name>
</person-group><article-title>Salinomycin as a potent anticancer stem cell agent: State of the art and future directions</article-title><source>Med. Res. Rev.</source><year>2022</year><volume>42</volume><fpage>1037</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1002/med.21870</pub-id><pub-id pub-id-type="pmid">34786735</pub-id>
</element-citation></ref><ref id="B86-medsci-13-00047"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>Z.</given-names></name>
<name><surname>Sperl</surname><given-names>B.</given-names></name>
<name><surname>Ullrich</surname><given-names>A.</given-names></name>
<name><surname>Knyazev</surname><given-names>P.</given-names></name>
</person-group><article-title>Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>12877</fpage><lpage>12890</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2657</pub-id><pub-id pub-id-type="pmid">25375092</pub-id>
</element-citation></ref><ref id="B87-medsci-13-00047"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>G.F.</given-names></name>
<name><surname>Li</surname><given-names>C.X.</given-names></name>
<name><surname>Liu</surname><given-names>Z.Q.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Cancer stem cell targets&#x02014;A review</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2016</year><volume>20</volume><fpage>2045</fpage><lpage>2051</lpage><pub-id pub-id-type="pmid">27249603</pub-id>
</element-citation></ref><ref id="B88-medsci-13-00047"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tefas</surname><given-names>L.R.</given-names></name>
<name><surname>Barb&#x00103;lat&#x00103;</surname><given-names>C.</given-names></name>
<name><surname>Tefas</surname><given-names>C.</given-names></name>
<name><surname>Tomu&#x0021b;&#x00103;</surname><given-names>I.</given-names></name>
</person-group><article-title>Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>1120</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13081120</pub-id><pub-id pub-id-type="pmid">34452081</pub-id>
</element-citation></ref><ref id="B89-medsci-13-00047"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antoszczak</surname><given-names>M.</given-names></name>
</person-group><article-title>A comprehensive review of salinomycin derivatives as potent anticancer and anti-CSCs agents</article-title><source>Eur. J. Med. Chem.</source><year>2019</year><volume>166</volume><fpage>48</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.01.034</pub-id><pub-id pub-id-type="pmid">30684870</pub-id>
</element-citation></ref><ref id="B90-medsci-13-00047"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Lou</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Dong</surname><given-names>Q.</given-names></name>
<name><surname>Han</surname><given-names>B.</given-names></name>
</person-group><article-title>Wnt blockers inhibit the proliferation of lung cancer stem cells</article-title><source>Drug Des. Devel Ther.</source><year>2015</year><volume>9</volume><fpage>2399</fpage><lpage>2407</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S76602</pub-id></element-citation></ref><ref id="B91-medsci-13-00047"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Luo</surname><given-names>Q.</given-names></name>
<name><surname>Ju</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>G.</given-names></name>
</person-group><article-title>Salinomycin Suppresses Tumorigenicity of Liver Cancer Stem Cells and Wnt/Beta-catenin Signaling</article-title><source>Curr. Stem Cell Res. Ther.</source><year>2021</year><volume>16</volume><fpage>630</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.2174/1574888X15666200123121225</pub-id><pub-id pub-id-type="pmid">31971116</pub-id>
</element-citation></ref><ref id="B92-medsci-13-00047"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koeck</surname><given-names>S.</given-names></name>
<name><surname>Amann</surname><given-names>A.</given-names></name>
<name><surname>Huber</surname><given-names>J.M.</given-names></name>
<name><surname>Gamerith</surname><given-names>G.</given-names></name>
<name><surname>Hilbe</surname><given-names>W.</given-names></name>
<name><surname>Zwierzina</surname><given-names>H.</given-names></name>
</person-group><article-title>The impact of metformin and salinomycin on transforming growth factor &#x003b2;-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines</article-title><source>Oncol. Lett.</source><year>2016</year><volume>11</volume><fpage>2946</fpage><lpage>2952</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.4323</pub-id><pub-id pub-id-type="pmid">27073581</pub-id>
</element-citation></ref><ref id="B93-medsci-13-00047"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hwang</surname><given-names>K.E.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Song</surname><given-names>I.S.</given-names></name>
<name><surname>Park</surname><given-names>C.</given-names></name>
<name><surname>Jung</surname><given-names>J.W.</given-names></name>
<name><surname>Park</surname><given-names>D.S.</given-names></name>
<name><surname>Oh</surname><given-names>S.H.</given-names></name>
<name><surname>Kim</surname><given-names>Y.S.</given-names></name>
<name><surname>Kim</surname><given-names>H.R.</given-names></name>
</person-group><article-title>Salinomycin suppresses TGF-&#x003b2;1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer</article-title><source>Int. J. Med. Sci.</source><year>2021</year><volume>18</volume><fpage>715</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.7150/ijms.50080</pub-id><pub-id pub-id-type="pmid">33437206</pub-id>
</element-citation></ref><ref id="B94-medsci-13-00047"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arafat</surname><given-names>K.</given-names></name>
<name><surname>Iratni</surname><given-names>R.</given-names></name>
<name><surname>Takahashi</surname><given-names>T.</given-names></name>
<name><surname>Parekh</surname><given-names>K.</given-names></name>
<name><surname>Al Dhaheri</surname><given-names>Y.</given-names></name>
<name><surname>Adrian</surname><given-names>T.E.</given-names></name>
<name><surname>Attoub</surname><given-names>S.</given-names></name>
</person-group><article-title>Inhibitory Effects of Salinomycin on Cell Survival, Colony Growth, Migration, and Invasion of Human Non-Small Cell Lung Cancer A549 and LNM35: Involvement of NAG-1</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e66931</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0066931</pub-id><pub-id pub-id-type="pmid">23805285</pub-id>
</element-citation></ref><ref id="B95-medsci-13-00047"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>K.Y.</given-names></name>
<name><surname>Yu</surname><given-names>S.N.</given-names></name>
<name><surname>Lee</surname><given-names>S.Y.</given-names></name>
<name><surname>Chun</surname><given-names>S.S.</given-names></name>
<name><surname>Choi</surname><given-names>Y.L.</given-names></name>
<name><surname>Park</surname><given-names>Y.M.</given-names></name>
<name><surname>Song</surname><given-names>C.S.</given-names></name>
<name><surname>Chatterjee</surname><given-names>B.</given-names></name>
<name><surname>Ahn</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2011</year><volume>413</volume><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.08.054</pub-id><pub-id pub-id-type="pmid">21871443</pub-id>
</element-citation></ref><ref id="B96-medsci-13-00047"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Su</surname><given-names>L.</given-names></name>
<name><surname>Zhong</surname><given-names>N.</given-names></name>
<name><surname>Hao</surname><given-names>X.</given-names></name>
<name><surname>Zhong</surname><given-names>D.</given-names></name>
<name><surname>Singhal</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
</person-group><article-title>Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells</article-title><source>Autophagy</source><year>2013</year><volume>9</volume><fpage>1057</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.4161/auto.24632</pub-id><pub-id pub-id-type="pmid">23670030</pub-id>
</element-citation></ref><ref id="B97-medsci-13-00047"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jangamreddy</surname><given-names>J.R.</given-names></name>
<name><surname>Ghavami</surname><given-names>S.</given-names></name>
<name><surname>Grabarek</surname><given-names>J.</given-names></name>
<name><surname>Kratz</surname><given-names>G.</given-names></name>
<name><surname>Wiechec</surname><given-names>E.</given-names></name>
<name><surname>Fredriksson</surname><given-names>B.A.</given-names></name>
<name><surname>Rao Pariti</surname><given-names>R.K.</given-names></name>
<name><surname>Cie&#x0015b;lar-Pobuda</surname><given-names>A.</given-names></name>
<name><surname>Panigrahi</surname><given-names>S.</given-names></name>
<name><surname>&#x00141;os</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Salinomycin induces activation of autophagy, mitophagy and affects mitochondrial polarity: Differences between primary and cancer cells</article-title><source>Biochim. Biophys. Acta</source><year>2013</year><volume>1833</volume><fpage>2057</fpage><lpage>2069</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2013.04.011</pub-id><pub-id pub-id-type="pmid">23639289</pub-id>
</element-citation></ref><ref id="B98-medsci-13-00047"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jangamreddy</surname><given-names>J.R.</given-names></name>
<name><surname>Panigrahi</surname><given-names>S.</given-names></name>
<name><surname>&#x00141;os</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Monitoring of autophagy is complicated--salinomycin as an example</article-title><source>Biochim. Biophys. Acta</source><year>2015</year><volume>1853</volume><fpage>604</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.12.022</pub-id><pub-id pub-id-type="pmid">25541282</pub-id>
</element-citation></ref><ref id="B99-medsci-13-00047"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Heinold</surname><given-names>A.</given-names></name>
<name><surname>Opelz</surname><given-names>G.</given-names></name>
<name><surname>Daniel</surname><given-names>V.</given-names></name>
<name><surname>Naujokat</surname><given-names>C.</given-names></name>
</person-group><article-title>Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2009</year><volume>390</volume><fpage>743</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.10.042</pub-id><pub-id pub-id-type="pmid">19835841</pub-id>
</element-citation></ref><ref id="B100-medsci-13-00047"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boehmerle</surname><given-names>W.</given-names></name>
<name><surname>Muenzfeld</surname><given-names>H.</given-names></name>
<name><surname>Springer</surname><given-names>A.</given-names></name>
<name><surname>Huehnchen</surname><given-names>P.</given-names></name>
<name><surname>Endres</surname><given-names>M.</given-names></name>
</person-group><article-title>Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice</article-title><source>J. Mol. Med.</source><year>2014</year><volume>92</volume><fpage>889</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1007/s00109-014-1155-0</pub-id><pub-id pub-id-type="pmid">24770997</pub-id>
</element-citation></ref><ref id="B101-medsci-13-00047"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ojo</surname><given-names>O.O.</given-names></name>
<name><surname>Bhadauria</surname><given-names>S.</given-names></name>
<name><surname>Rath</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Correction: Dose-dependent adverse effects of salinomycin on male reproductive organs and fertility in mice</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0226872</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0226872</pub-id><pub-id pub-id-type="pmid">31856246</pub-id>
</element-citation></ref><ref id="B102-medsci-13-00047"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tung</surname><given-names>C.L.</given-names></name>
<name><surname>Chen</surname><given-names>J.C.</given-names></name>
<name><surname>Wu</surname><given-names>C.H.</given-names></name>
<name><surname>Peng</surname><given-names>Y.S.</given-names></name>
<name><surname>Chen</surname><given-names>W.C.</given-names></name>
<name><surname>Zheng</surname><given-names>H.Y.</given-names></name>
<name><surname>Jian</surname><given-names>Y.J.</given-names></name>
<name><surname>Wei</surname><given-names>C.L.</given-names></name>
<name><surname>Cheng</surname><given-names>Y.T.</given-names></name>
<name><surname>Lin</surname><given-names>Y.W.</given-names></name>
</person-group><article-title>Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells</article-title><source>Exp. Cell Res.</source><year>2017</year><volume>357</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2017.04.026</pub-id><pub-id pub-id-type="pmid">28454878</pub-id>
</element-citation></ref><ref id="B103-medsci-13-00047"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ko</surname><given-names>J.C.</given-names></name>
<name><surname>Zheng</surname><given-names>H.Y.</given-names></name>
<name><surname>Chen</surname><given-names>W.C.</given-names></name>
<name><surname>Peng</surname><given-names>Y.S.</given-names></name>
<name><surname>Wu</surname><given-names>C.H.</given-names></name>
<name><surname>Wei</surname><given-names>C.L.</given-names></name>
<name><surname>Chen</surname><given-names>J.C.</given-names></name>
<name><surname>Lin</surname><given-names>Y.W.</given-names></name>
</person-group><article-title>Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression</article-title><source>Biochem. Pharmacol.</source><year>2016</year><volume>122</volume><fpage>90</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.09.022</pub-id><pub-id pub-id-type="pmid">27666600</pub-id>
</element-citation></ref><ref id="B104-medsci-13-00047"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelgalil</surname><given-names>A.A.</given-names></name>
<name><surname>Al-Kahtani</surname><given-names>H.M.</given-names></name>
<name><surname>Al-Jenoobi</surname><given-names>F.I.</given-names></name>
</person-group><article-title>Erlotinib</article-title><source>Profiles Drug Subst. Excip. Relat. Methodol.</source><year>2020</year><volume>45</volume><fpage>93</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/bs.podrm.2019.10.004</pub-id><pub-id pub-id-type="pmid">32164971</pub-id>
</element-citation></ref><ref id="B105-medsci-13-00047"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rose</surname><given-names>M.C.</given-names></name>
<name><surname>Kostyanovskaya</surname><given-names>E.</given-names></name>
<name><surname>Huang</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer</article-title><source>Genom. Proteom. Bioinform.</source><year>2014</year><volume>12</volume><fpage>198</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.gpb.2014.10.003</pub-id></element-citation></ref><ref id="B106-medsci-13-00047"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michalak</surname><given-names>M.</given-names></name>
<name><surname>Lach</surname><given-names>M.S.</given-names></name>
<name><surname>Antoszczak</surname><given-names>M.</given-names></name>
<name><surname>Huczy&#x00144;ski</surname><given-names>A.</given-names></name>
<name><surname>Suchorska</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>537</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25030537</pub-id><pub-id pub-id-type="pmid">31991882</pub-id>
</element-citation></ref><ref id="B107-medsci-13-00047"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>Z.Z.</given-names></name>
<name><surname>Nie</surname><given-names>P.P.</given-names></name>
<name><surname>Li</surname><given-names>Y.W.</given-names></name>
<name><surname>Hou</surname><given-names>B.X.</given-names></name>
<name><surname>Shi</surname><given-names>X.P.</given-names></name>
<name><surname>Ma</surname><given-names>Z.K.</given-names></name>
<name><surname>Han</surname><given-names>B.W.</given-names></name>
<name><surname>Luo</surname><given-names>X.Y.</given-names></name>
</person-group><article-title>Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>22414</fpage><lpage>22432</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5628</pub-id><pub-id pub-id-type="pmid">26461472</pub-id>
</element-citation></ref><ref id="B108-medsci-13-00047"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skeberdyt&#x00117;</surname><given-names>A.</given-names></name>
<name><surname>Sarapinien&#x00117;</surname><given-names>I.</given-names></name>
<name><surname>Aleksander-Krasko</surname><given-names>J.</given-names></name>
<name><surname>Stankevi&#x0010d;ius</surname><given-names>V.</given-names></name>
<name><surname>Su&#x0017e;ied&#x00117;lis</surname><given-names>K.</given-names></name>
<name><surname>Jarmalait&#x00117;</surname><given-names>S.</given-names></name>
</person-group><article-title>Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>17744</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-35815-4</pub-id><pub-id pub-id-type="pmid">30531808</pub-id>
</element-citation></ref><ref id="B109-medsci-13-00047"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skeberdyt&#x00117;</surname><given-names>A.</given-names></name>
<name><surname>Sarapinien&#x00117;</surname><given-names>I.</given-names></name>
<name><surname>Krasko</surname><given-names>J.A.</given-names></name>
<name><surname>Barakauskien&#x00117;</surname><given-names>A.</given-names></name>
<name><surname>&#x0017d;ilionyt&#x00117;</surname><given-names>K.</given-names></name>
<name><surname>Prokarenkait&#x00117;</surname><given-names>R.</given-names></name>
<name><surname>Su&#x0017e;ied&#x00117;lis</surname><given-names>K.</given-names></name>
<name><surname>Bukelskien&#x00117;</surname><given-names>V.</given-names></name>
<name><surname>Jarmalait&#x00117;</surname><given-names>S.</given-names></name>
</person-group><article-title>Salinomycin and dichloroacetate synergistically inhibit Lewis lung carcinoma cell proliferation, tumor growth and metastasis</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2020</year><volume>523</volume><fpage>874</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.12.107</pub-id><pub-id pub-id-type="pmid">31955885</pub-id>
</element-citation></ref><ref id="B110-medsci-13-00047"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>M.</given-names></name>
<name><surname>Shen</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Su</surname><given-names>S.</given-names></name>
<name><surname>Lv</surname><given-names>X.</given-names></name>
<name><surname>Qian</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
</person-group><article-title>The antitumor effect of diisopropylamine dichloroacetate on non-small cell lung cancer and its influence on the tumor immune microenvironment</article-title><source>Front. Oncol.</source><year>2024</year><volume>29</volume><elocation-id>1447828</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2024.1447828</pub-id><pub-id pub-id-type="pmid">39267851</pub-id>
</element-citation></ref><ref id="B111-medsci-13-00047"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Yan</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Jin</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Pang</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
<name><surname>Xiao</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Modulating autophagy in the tumor microenvironment with a salinomycin-loaded liposome hybrid nanovesicle system for tumor immunotherapy</article-title><source>Nanotoday</source><year>2025</year><volume>61</volume><fpage>102644</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2025.102644</pub-id></element-citation></ref><ref id="B112-medsci-13-00047"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaghari-Tabari</surname><given-names>M.</given-names></name>
<name><surname>Hassanpour</surname><given-names>P.</given-names></name>
<name><surname>Sadeghsoltani</surname><given-names>F.</given-names></name>
<name><surname>Malakoti</surname><given-names>F.</given-names></name>
<name><surname>Alemi</surname><given-names>F.</given-names></name>
<name><surname>Qujeq</surname><given-names>D.</given-names></name>
<name><surname>Asemi</surname><given-names>Z.</given-names></name>
<name><surname>Yousefi</surname><given-names>B.</given-names></name>
</person-group><article-title>CRISPR/Cas9 gene editing: A new approach for overcoming drug resistance in cancer</article-title><source>Cell Mol. Biol. Lett.</source><year>2022</year><volume>27</volume><elocation-id>49</elocation-id><pub-id pub-id-type="doi">10.1186/s11658-022-00348-2</pub-id><pub-id pub-id-type="pmid">35715750</pub-id>
</element-citation></ref><ref id="B113-medsci-13-00047"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jovic</surname><given-names>D.</given-names></name>
<name><surname>Liang</surname><given-names>X.</given-names></name>
<name><surname>Zeng</surname><given-names>H.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Xu</surname><given-names>F.</given-names></name>
<name><surname>Luo</surname><given-names>Y.</given-names></name>
</person-group><article-title>Single-cell RNA sequencing technologies and applications: A brief overview</article-title><source>Clin. Transl. Med.</source><year>2022</year><volume>12</volume><fpage>e694</fpage><pub-id pub-id-type="doi">10.1002/ctm2.694</pub-id><pub-id pub-id-type="pmid">35352511</pub-id>
</element-citation></ref><ref id="B114-medsci-13-00047"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slovin</surname><given-names>S.</given-names></name>
<name><surname>Carissimo</surname><given-names>A.</given-names></name>
<name><surname>Panariello</surname><given-names>F.</given-names></name>
<name><surname>Grimaldi</surname><given-names>A.</given-names></name>
<name><surname>Bouch&#x000e9;</surname><given-names>V.</given-names></name>
<name><surname>Gambardella</surname><given-names>G.</given-names></name>
<name><surname>Cacchiarelli</surname><given-names>D.</given-names></name>
</person-group><article-title>Single-Cell RNA Sequencing Analysis: A Step-by-Step Overview</article-title><source>Methods Mol. Biol.</source><year>2021</year><volume>2284</volume><fpage>343</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1307-8_19</pub-id><pub-id pub-id-type="pmid">33835452</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="medsci-13-00047-f001"><label>Figure 1</label><caption><p>Schematic representation of mechanisms of action of DCA, both alone and its synergy in combination with other anticancer agent(s).</p></caption><graphic xlink:href="medsci-13-00047-g001" position="float"/></fig><fig position="float" id="medsci-13-00047-f002"><label>Figure 2</label><caption><p>Schematic representation of mechanisms of action of SAL alone and its synergy in combination with other anticancer agent(s).</p></caption><graphic xlink:href="medsci-13-00047-g002" position="float"/></fig><table-wrap position="float" id="medsci-13-00047-t002"><object-id pub-id-type="pii">medsci-13-00047-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary of in vitro studies on SAL alone and its combination with other therapeutic agent(s).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target(s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL</td><td align="center" valign="middle" rowspan="1" colspan="1">MHCC97H</td><td align="center" valign="middle" rowspan="1" colspan="1">Wnt/&#x003b2;-catenin </td><td align="center" valign="middle" rowspan="1" colspan="1">SAL suppresses the stemness of LCSCs via inhibiting Wnt/&#x003b2;-catenin signaling.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B91-medsci-13-00047" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL</td><td align="center" valign="middle" rowspan="1" colspan="1">A549, HCC4006</td><td align="center" valign="middle" rowspan="1" colspan="1">TGF&#x003b2;, EMT process</td><td align="center" valign="middle" rowspan="1" colspan="1">SAL interrupts EMT by inhibiting TGF&#x003b2; signaling.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B92-medsci-13-00047" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL</td><td align="center" valign="middle" rowspan="1" colspan="1">A549, H460</td><td align="center" valign="middle" rowspan="1" colspan="1">TGF&#x003b2;, AMPK/SIRT1</td><td align="center" valign="middle" rowspan="1" colspan="1">SAL inhibits TGF&#x003b2; through AMPK/SIRT1 signaling pathways.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B93-medsci-13-00047" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL</td><td align="center" valign="middle" rowspan="1" colspan="1">A549, LNM35</td><td align="center" valign="middle" rowspan="1" colspan="1">NAG-1,<break/>intracellular ROS</td><td align="center" valign="middle" rowspan="1" colspan="1">SAL inhibits growth, migration, and invasion via inducing apoptosis through targeting NAG-1.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B94-medsci-13-00047" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL</td><td align="center" valign="middle" rowspan="1" colspan="1">LNCaP, PC-3, DU-145, RWPE-1</td><td align="center" valign="middle" rowspan="1" colspan="1">Bax protein, cytochrome-c, intracellular ROS</td><td align="center" valign="middle" rowspan="1" colspan="1">SAL induces apoptosis by elevating intracellular ROS, cytochrome-c release to cytoplasm, Bax protein translocation to mitochondria, and caspase-3 substrate activation.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B95-medsci-13-00047" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL</td><td align="center" valign="middle" rowspan="1" colspan="1">A549, Calu-1, H157</td><td align="center" valign="middle" rowspan="1" colspan="1">Autophagy, ATF4-DDIT3/CHOP-TRIB3-AKT1-mTOR</td><td align="center" valign="middle" rowspan="1" colspan="1">SAL induces apoptosis in lung cancer cells via autophagic flux.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B96-medsci-13-00047" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL</td><td align="center" valign="middle" rowspan="1" colspan="1">PC-3, SKBR3, MDAMB468, MEF</td><td align="center" valign="middle" rowspan="1" colspan="1">Autophagy, mitophagy</td><td align="center" valign="middle" rowspan="1" colspan="1">SAL decreases cellular ARP, but induced autophagy can counteract its apoptotic mechanisms if not used in combination with autophagy inhibitors.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B97-medsci-13-00047" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL</td><td align="center" valign="middle" rowspan="1" colspan="1">Molt-4 CD4+ T-cells</td><td align="center" valign="middle" rowspan="1" colspan="1">Apoptosis</td><td align="center" valign="middle" rowspan="1" colspan="1">SAL is able to induce apoptosis in apoptotic-resistant leukemia cells.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B98-medsci-13-00047" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL, metformin</td><td align="center" valign="middle" rowspan="1" colspan="1">HCC4006, <break/>NCI-H1975,<break/>NCI-H2122, HCC95, NCI-H3122</td><td align="center" valign="middle" rowspan="1" colspan="1">AKT, ERK1/2, mTOR, p70 s6K</td><td align="center" valign="middle" rowspan="1" colspan="1">In combination with metformin, SAL induces cell death and decreases cell density/viability.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B86-medsci-13-00047" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL, erlotinib</td><td align="center" valign="middle" rowspan="1" colspan="1">H1703, H1975</td><td align="center" valign="middle" rowspan="1" colspan="1">AKT-CA, TS</td><td align="center" valign="middle" rowspan="1" colspan="1">In combination with erlotinib, SAL inhibits TS and AKT signaling.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B102-medsci-13-00047" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL, cisplatin</td><td align="center" valign="middle" rowspan="1" colspan="1">A549, H1703</td><td align="center" valign="middle" rowspan="1" colspan="1">AKT-CA</td><td align="center" valign="middle" rowspan="1" colspan="1">SAL and cisplatin synergistically inhibit lung cancer cells via AKT inhibition.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B103-medsci-13-00047" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAL, cisplatin, <break/>5-fluorouracil, gemcitabine</td><td align="center" valign="middle" rowspan="1" colspan="1">A2780 CDDP, <break/>SK-OV-3 CDDP, A2780, <break/>SK-OV-3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cisplatin resistance</td><td align="center" valign="middle" rowspan="1" colspan="1">SAL reverses cisplatin resistance in ovarian cancer cells in combination with 5-flurouracil and gemcitabine.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B106-medsci-13-00047" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SAL, gefitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SW1116, LOVO, HCT-116, SW480, HT-29, NCM460</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AKT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SAL and gefitinib&#x02019;s combination induces apoptosis in gefitinib-resistant cell lines and overcomes gefitinib resistance in Ras-overexpressing cells.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-medsci-13-00047" ref-type="bibr">107</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">SAL</italic>, salinomycin; <italic toggle="yes">AMPK</italic>, adenosine monophosphate-activated protein kinase; mTOR, mammalian target of rapamycin complex 1; <italic toggle="yes">Wnt</italic>, Wingless-related integration site pathway; <italic toggle="yes">AKT-CA</italic>, Ak strain transforming protein kinase B (Ca<sup>2+</sup>); <italic toggle="yes">TS</italic>, thymidylate synthase; <italic toggle="yes">TGF&#x003b2;</italic>, transforming growth factor beta; <italic toggle="yes">EMT</italic>, epithelial&#x02013;mesenchymal transition; <italic toggle="yes">ROS</italic>, reactive oxygen species; <italic toggle="yes">SIRT1</italic>, sirtuin gene 1; <italic toggle="yes">NAG-1</italic>, NSAID-activated gene; <italic toggle="yes">ATF4</italic>, activating transcription factor 4; <italic toggle="yes">DDIT3/CHOP</italic>, DNA damage-inducible transcript 3/C/EBP homologous protein; <italic toggle="yes">TRIB3</italic>, Tribbles pseudokinase 3; <italic toggle="yes">AKT1</italic>, AKT serine/threonine kinase 1.</p></fn></table-wrap-foot></table-wrap></floats-group></article>